University of North Dakota

UND Scholarly Commons
Theses and Dissertations

Theses, Dissertations, and Senior Projects

January 2019

Avian IgY As An Immunotherapy For Flaviviral
Infections
Kyle O'donnell

Follow this and additional works at: https://commons.und.edu/theses
Recommended Citation
O'donnell, Kyle, "Avian IgY As An Immunotherapy For Flaviviral Infections" (2019). Theses and Dissertations. 2478.
https://commons.und.edu/theses/2478

This Dissertation is brought to you for free and open access by the Theses, Dissertations, and Senior Projects at UND Scholarly Commons. It has been
accepted for inclusion in Theses and Dissertations by an authorized administrator of UND Scholarly Commons. For more information, please contact
zeineb.yousif@library.und.edu.

AVIAN IGY AS AN IMMUNOTHERAPY FOR FLAVIVIRAL INFECTIONS

By

Kyle Lee O’Donnell

A Dissertation

Submitted to the Graduate Faculty
of the
University of North Dakota

In partial fulfillment of the requirements
for the degree of
Doctor of Philosophy

Grand Forks, North Dakota
May 2019

PERMISSION
Title: Avian IgY as an Immunotherapy for Flaviviral Infections
Department: Biomedical Sciences
Degree: Doctor of Philosophy

In presenting this dissertation in partial fulfillment of the requirements for a graduate
degree from the University of North Dakota, I agree that the library of this University
shall make it freely available for inspection. I further agree that permission for extensive
copying for scholarly purposes may be granted by the professor who supervised my
dissertation work or, in his absence, by the Chairperson of the department or the dean
of the School of Graduate Studies. It is understood that any copying or publication or
other use of this dissertation or part thereof for financial gain shall not be allowed
without my written permission. It is also understood that due recognition shall be given
to me and to the University of North Dakota in any scholarly use which may be made of
any material in my dissertation.
Kyle O’Donnell
April 24th, 2019

ii

Acknowledgments
I would like to express my deepest gratitude to everyone who has provided guidance
and support throughout my graduate research career. To top that list is my advisor Dr.
Bradley, for allowing me the freedom to develop my own scientific ideas and to develop
into an independent scientist while still continually providing me with encouragement
and support when needed. His genuine commitment to the professional development of
young scientist and continued progression of scientific knowledge makes me honored to
have learned under him and I hope to one day carry that same standard when I
establish my own lab. I would also like to thank Dr. Vaughan for broadening my
scientific perspective from not only focusing on the clinical aspect, but the pathogenic
process as a whole. I believe this has not only allowed me to grow as a more complete
virologist, but given me a unique insight that I hope to apply to new projects in the
future. I would also like to thank the remaining members of my dissertation committee
Dr. Nilles, Dr. Sharma, and Dr. Combs for always having your doors open to me
whenever I had a question I needed insight to and for furthering my career with either
asking questions at seminars, letters of recommendation, to casual scientific talks in the
hallways after invited speakers. I valued each of your thoughts and suggestions highly
and they greatly impacted my graduate career development. I would also like to thank
the rest of the Biomedical Sciences faculty for numerous discussions and instructions
provided. I would like to thank members of the Bradley lab former and present for
riveting scientific discussions and keeping me sane after all nighters. I would like to
iii

thank Steve Adkins for assisting in the microinjections of mosquitoes and your unique
insights. I would like to thank Dr. Peter Knopick and Dr. Travis Alvine for their
mentorship and friendship. Both of you challenged me intellectually and gave important
insights into my work as well as your own. I am a far better scientist for working with
both of you. I would like to thank the numerous undergraduate students whom worked
in the Bradley lab and assisted with my projects. Science can never be done completely
alone and their help was greatly appreciated. Finally, I would like to thank my family for
not only putting up with me constantly talking about virology at family functions, but for
providing me the support when needed and for instilling in me that hard work will pay off
in the end.

iv

Table of Contents
Acknowledgments…………………………………………………………………………..….iii
List of Figures …………………………………………………………………………………..vi
List of Tables …………………………………………………………………………………..vii
Abstract………………………………………………………………………………..………..viii
Chapter I: Introduction to Flaviviruses ………………………………………………………1
Chapter II: Introduction to Avian IgY…………………………………………………………11
Chapter III: Zika Virus Vector Competency ………………………………………………...22
Chapter IV: Avian IgY as an Immunotherapy for Zika Virus……………………………....41
Chapter V: Avian antibodies targeting dengue virus NS1 neutralize infection in vitro and
confer protection against lethal dengue disease in a mouse model……………………..73
Chapter VI: Discussion……………………………………………………………………..…99
References: …………………………………………………………………………………..107

v

List of Figures

Figure 1: Enzootic and epidemic transmission cycle of Zika virus………………………24
Figure 2: Midgut and disseminated infection of Ae. vexans and Ae. aegypti…………...31
Figure 3: Anti-ZIKV IgY purification………………………………………………………….55
Figure 4: Anti-ZIKV IgY neutralizes ZIKV in vitro without antibody-dependent
enhancement…………………………………………………………………………………..57
Figure 5: Therapeutic efficacy of anti-ZIKV IgY in vivo……………………………………59
Figure 6: Viral load reduction upon treatment with anti-ZIKV IgY………………………..60
Figure 7: Epitope mapping of structural and non-structural genes………………………63
Figure 8: Epitope mapping of structural and non-structural genes………………………64
Figure 9: Anti-DENV2 NS1 IgY neutralizes DENV2 in vitro………………………………84
Figure 10: NS1 epitope IgY binding multiple DENV NS1 from varying serotypes……...86
Figure 11: Antibody dependent assay of anti-DENV NS1 IgY with DENV and ZIKV…..88
Figure 12: Soluble NS1 blockade and TEER assay……………………………………….90
Figure 13: IFNAR KO mice protected in vivo……………………………………………….93
Figure 14: Cytotoxicity of Vero cells treated with anti-DENV2 IgY infected with ZIKV.101
Figure 15: Anti-NS1 Zika IgY and anti-NS5 Zika IgY does not neutralize ZIKV infection
in vitro………………………………………………………………………………………….103

vi

List of Tables
Table 1: Infection and dissemination of Zika virus in wild-caught and colonized
mosquitoes……………………………………………………………………………………..32
Table 2: Transmission of Zika virus by mosquitoes 16 to 17 days after being inoculated
intrathoracically………………………………………………………………………………..35
Table 3: Corresponding epitopes to the heat maps of structural and non-structural
proteins of DENV recognized by anti-ZIKV IgY and naïve IgY…………………………...65
Table 4: Corresponding epitopes to the heat maps of structural and non-structural
proteins of WENV recognized by anti-ZIKV IgY and naïve IgY…………………………..66
Table 5: Corresponding epitopes to the heat maps of structural and non-structural
proteins of YFV recognized by anti-ZIKV IgY and naïve IgY……………………………..68

vii

Abstract
Flaviviruses compose a group of positive single strand RNA viruses. This group
possess 70 individual viruses that cause disease in humans and animals. This group
contains the most prevalent arbovirus dengue virus (DENV) and a recently emerging
arbovirus zika virus (ZIKV). Both DENV and ZIKV represent significant world health
threats and both viruses, at the moment, are contained to tropical and sub tropical
regions due to vector habitat restrictions. DENV can cause severe hemorrhagic fever
termed dengue hemorrhagic fever and dengue shock syndrome depending on the
extent of vascular permeability. The disease burden attributed to dengue infection is
approximately 390 million infections per year. Of these infections, 96 million will result in
clinical disease and 500,000 patients require hospitalization resulting in 25,000 deaths a
year. ZIKV presents a less severe disease pathology, with a majority of infections in
healthy adults being asymptomatic. The more severe infections in adults result in an
autoimmune disease called Guillain-Barre syndrome. What caused the world health
organization to declare ZIKV a world health emergency in 2016 is the viruses’ ability to
transverse the placenta barrier and infect a developing fetus. The most severe symptom
associated with in utero infection is the development of microcephaly, which leads to
severe cognitive impairment. As case studies expand and the disease pathology of
ZIKV is more fully understood a class of symptoms termed congenital zika syndrome
fully classifies the extent of cognitive abnormalities induced by this virus. A
commonality of these two viruses is that there are no approved treatments for either of
viii

these viral infections. A vaccine for DENV was recently introduced, but due to
immunological complications it was withdrawn from distribution. A significant issue to
combat with the development of therapies for dengue and zika viral infection is the
induction of antibody dependent enhancement (ADE). ADE is mediated when crossreactive low affinity antibodies bind to the virus and are internalized via the FcγR on
myeloid cells, but do not neutralize the virus resulting in an induction of proinflammatory cytokines and increased viral titer. In the studies presented here we
hypothesized that the utilization of avian IgY, which does not interact with mammalian
Fc receptors, would provide a viable therapy for ZIKV and DENV viral infection.
Polyvalent anti-ZIKV IgY was purified from eggs of ZIKV immunized geese. The purified
anti-ZIKV IgY preparation was assessed for it’s ability to neutralize ZIKV infection in
vitro and in vivo. We also assessed for the ability of polyvalent anti-ZIKV IgY to enhance
viral infection in vitro. Our data suggests that anti-ZIKV IgY is able to neutralize ZIKV
infection in vitro and in vivo without inducing ADE. Our data also demonstrates novel
viral epitopes recognized in our polyvalent anti-ZIKV IgY preparation. Previously our lab
had established that polyvalent anti-DENV IgY was able to neutralize ZIKV infection in
vitro and in vivo without inducing ADE. Novel non-structural protein 1 (NS1) epitopes
were recognized and determined by microarray analysis. In our study we expand upon
this work and determine if the novel NS1 IgY have the ability to neutralize DENV
infection in vitro and in vivo. Our data suggests that anti-NS1 IgY has the ability to
neutralize DENV infection in vitro and in vivo. This is highly atypically of anti-NS1 DENV
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antibodies, which typically only exhibit efficacy in vivo. Thus our data suggests not only
a novel epitope of neutralization, but a unique neutralization mechanism distinctive to
IgY. Due to the emergence of zika virus as a global health threat a greater vector
competency profile was needed to be conducted to estimate the true pathogenic range
and which populations could be potentially at risk. In collaboration with the Biology
department at UND we conducted vector competency studies of mosquito species
native to the region. To our surprise our common pest mosquito Aedes vexans was not
only able to establish a midgut infection, but also developed disseminated infection in a
small percentage of cases. We then tested the ability for the mosquito to transmit the
virus under laboratory settings and Aedes vexans were able to transmit the virus at a
much higher rate than the positive control population Aedes aegypti. This study greatly
expands the potential geographical area that zika virus could potentially spread to, as
Aedes vexans is common in many temperate climates across North America and
Europe.
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Chapter I
Introduction Flaviviruses
Flaviviruses compose a group of positive single strand RNA viruses. This group
possesses 70 individual viruses that cause disease in humans and animals. All viruses
in this group are named for the location in which they were discovered. This is divergent
from many other viral groups which rely on genetic characteristics for nomenclature.
Many of these pathogenic flaviviruses are arboviruses which indicates they are spread
by mosquitoes or ticks. Of the 70 viruses that cause diseases 5 of them are of great
public health concern for humans they are; Dengue virus, West Nile virus, Japanese
encephalitis virus, Yellow fever virus, and Zika virus. Flaviviruses encode 10 genes
three structural genes and seven non-structural genes. The structural genes are the
lipid envelope (E) the pre-membrane (prM) and the internal capsid (C). These proteins
are involved in composing the extra-RNA protective matrix, receptor fusion of an
infectious virion, and immune evasion. The seven non-structural proteins are nonstructural protein 1 (NS1), non-structural protein 2a/b (NS2a, NS2b), non-structural
protein 3 (NS3), non-structural protein 4a/b (NS4a, NS4b), and non-structural protein 5
(NS5). The primary function of these proteins in developing the viral replication complex
and copying the viral RNA for the production of mature virions. Many non-structural
proteins also possess immune evasive properties particularly against intracellular innate
pattern recognition receptors. Initially the viral RNA encodes a polyprotein precursor
which is then enzymatically cleaved to individual viral proteins.
1

In further detail a model virion to describe viral replication of this group is DENV. The 50
nm viral particle attaches to an extracellular receptor on susceptible host cells. The
primary host receptor has not been fully elucidated, but many receptors have been
demonstrated experimentally. The primary candidate is DC-SIGN/L-SIGN expressed on
dendritic cells and macrophages (1, 2, 3). Heparan sulfate receptor is also a prime
candidate as it has been identified as a receptor in multiple in vitro models of dengue
virus infection including Vero cells, BHK-21 cells, and SW-13 cells (4, 5). Mannose
receptor may be a target for viral attachment on macrophages (6). These three
receptors are the only receptors identified that are involved in the internalization of all
four DENV serotypes. The virion is then internalized by clathrin mediated endocytosis
once the endosomal pH starts to lower a conformational change of the viral envelope
exposes the DIII fusion loop that allow for the viral envelop to fuse with the endosomal
membrane and release the viral ribonucleocpasid into the cytoplasm (7). Viral nonstructural proteins and host factors co-integrate and form a membrane associated
replication complex that allows for viral RNA replication to take place. The viral
replication complex is formed inside a vesicular compartment of the endoplasmic
reticulum (ER) lumen. NS4A and B anchor the complex on the cytoplasmic side and a
NS1 dimer anchors the ER lumen side. Protein-protein interactions between NS1 and
NS4A and B has been demonstrated (8). NS4B is also in direct contact with NS3 which
functions as the RNA helicase (9). This interaction is not complete without NS2B which
is a co-factor for NS3 helicase activity (10). NS5 is the RNA dependent RNA
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polymerase and methyltranserase which is important for RNA capping of the new viral
genome. NS2A anchors the viral RNA to the ER lumen to allow for complete replication
(11). The newly synthesized RNA is packaged by the capsid protein to start the
formation of a new immature viral particle. The prM and E proteins form heterodimers in
the ER lumen. Once integrated together into trimers a curved lattice structure is formed
which directs virion budding (12, 13). The immature virion then travels through the
trans-Golgi network. The moderately acidic pH of the trans-Golgi network induces a
conformational change of the prM/E trimers to lie flat on the surface of the particle. This
restructuring is critical to allow for the cellular endoprotease furin to cleave prM to
generate the mature M and dissociate the “pr” particle that is then secreted from
infected cells and act to evade host immune responses (14, 15, 16). The now mature
virion is exocytosed from the cell preferentially through lipid rafts harboring NS1 dimers.
As stated previously not only is the mature virion secreted but also pr and NS1 hexamer
which as involved in immune evasion and increase in disease pathology.
Flaviviral pathogenesis can be separated into two separate clades based on the
type of clinical manifestations presented in patients. The first is clade are the viruses
that induce hemorrhaging for the purpose of this dissertation Dengue virus will be used
as an example as it is applicable to future studies in combating the pathogenesis. The
second clade are those that induce neurological symptoms, Zika virus will be used as
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an example in this dissertation even though it possesses unique characteristics and is
not a stereotypical example of this clade.
Infection with any of the four serotypes of DENV in a majority of cases result in
an asymptomatic infection. Infections may progress into a wide variety of clinical
manifestations ranging from mild flu like symptoms to more severe symptoms including
vascular permeability and shock. The World Health Organization has four grades of
dengue hemorrhagic fever (DHF). Grades I and II are less severe and do not induce
shock. Grades III and IV cases are more severe and contain hypovolemic shock as a
symptom. Pathology of DENV can be broken down into three major organs that play a
role: immune system, the liver, and endothelial cell linings of blood vessels. Initial
introduction of DENV to the host via the mosquito proboscis into the skin, which allows
for the infection of Langerhans cells (17). These residential dendritic cells then migrate
to local lymph nodes which exposes infiltrating monocytes and macrophages for
infection. Once these cells have become infected the virus is then able to spread
throughout the limbic system continually encountering susceptible cells for continued
viral infection and replication (18-20). Secondary infection with a heterotypic serotype of
DENV can result in antibody mediated infection of monocytes, but this will be explained
in greater detail in the section on antibody dependent enhancement (ADE).
Mononuclear cells primary die via apoptosis which in turns stimulates inflammatory
mediators which contributes to the disease pathology (20, 21, 22). Organ pathology
traditionally has been a challenge due to the lack of resources in endemic areas of this

4

disease and cultural traditions that inhibit autopsies from being performed. Virus has
been identified in patients who died within 36 hour of developing shock in the skin, liver,
spleen, lymph nodes, kidney, bone marrow, lung, thymus, and brain (23). Infectious
virions could only be cultured from the liver and peripheral blood mononuclear cells
(PBMCs), which could indicate that the virus in the other organs was degraded or in an
immature state. Liver is typically associated with DENV infection in humans and mice. A
unique attribute of this area of pathology is that little inflammation has been detected in
the liver and the tissue disruption is directly viral related as compared to a secondary
immune scaring event. Extensive work form the Eva Harris lab has demonstrated the
pathogenic role of NS1 on the endothelial glycocalyx. This occurs when circulating
pentameric NS1 molecules bind to the surface of endothelial cells in capillary beds. The
interaction between the endothelial cell surface and NS1 results in the up regulation of
sialadases Neu1-3, which leads to the cleavage of sialic acid on the surface of the
endothelial cells. The binding of NS1 also induces an increased expression of cathepsin
L, which in turns over expresses heperanase and results in the cleavage of hepran
sulfate and hepran sulfate proteoglycans. When all of these processes occur
simultaneously they result in loss of endothelial glycocalyx layer and barrier integrity
(24).
Taking a closer look at the immune response elicited by DENV not all are
favorable to the host. Four immunological events can contribute to DENV pathology:
complement activation, ADE, cross reactive T-cells, and soluble factors. The
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complement system is an integral part of the humoral innate response and can act
rapidly when induced by a pathogen antigen. It has been previously demonstrated that
high levels of complement activation subunits C3a and C5a are found circulating in
patient blood whom develop DHF and dengue shock syndrome (DSS) (25, 26). NS1
can induce antibodies that can target the dimeric NS1 expressed on infected cells. In
other cases, these antibodies can target cells that NS1 is binding to inducing antibody
mediated complement lyses of uninfected cells as well. (27). The generation of less
than ideal antibodies in DENV infection is a common theme throughout the infection
process. DENV utilizes a number of factors to evade or miss lead the antibody response
to make it as ineffective as possible, such mechanism have previously been described
as in NS1 over activating the complement system, pr is a potent B cell antigen that has
no neutralization properties to a mature virion effectively DENV uses it as an antigenic
decoy. One of the critical follies in the antibody repertoire of DENV infection is the
production of high affinity and sub neutralizing antibodies. These antibodies have high
affinity to the primary serotype the patient is infected with but on a secondary
heterotypic infection they will bind, but not neutralize the virus enabling the virus to
utilize FcγR’s as an additional route of infecting cells. This mechanism will be discussed
later in a separate section. T cells like antibodies can be a double edge sword in DENV
pathogenesis. Memory cross reactive CD8 T cells can provide robust protection (28),
but they can also contribute to pathogenesis leading to the “original antigenic sin
hypothesis.” The basis for this hypothesis is that low-avidity cross reactive CD8 T cells
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would preferentially expand compared to high-avidity cross reactive CD8 T cells. The
high-avidity cross reactive CD8 T cells produce robust pro- and anti-inflammatory
cytokine response resulting in a balanced immune response that has the ability to lyse
virally infected cells and then mitigate the immunological scaring due to the lysis
process. Due to the robust activation of these cells they rapidly undergo apoptosis. This
leaves a window for the low avidity CD8 T cells to preferentially expand in the place of
the now expired high avidity counter parts. The low avidity CD8 T cells have the ability
to produce high levels of pro-inflammatory cytokines, but lack effective cytolytic activity
and produce minimal levels of anti-inflammatory cytokines to reduce immunological
scaring (29, 30). This has lead to the development of a cytokine storm in severe dengue
patients. Through multiple patient screenings a panel of cytokines has been complied
that are consistently higher in plasma levels with patients with severe dengue disease
these are; IL-1β, IL-2, IL-4, IL-6, IL-7, IL-8, IL-10, IL-13, IL-18, TGF-1β, TNFα and IFNγ
(31,32,33,34,35,36,37,38,39,40,41). The issue for researchers is to determine which
cytokine or combination of cytokines are actually inducing the pathology and which are
still protective. One of the key hallmarks of severe dengue disease is vascular
permeability which can partially be attributed to the over production of TNFα and IL-6
(42).The original antigenic sin hypothesis has also been observed in LCMV, Influenza,
and MCMV (43, 44, 29). It is likely that not only factor contributes wholly to DENV
pathogenesis. Some factors such as host genetic background are still being researched
and are not fully understood how anomalies interact with the pathogenesis of the virus.
7

By placing the subsequent sections together an integrated mechanism of pathogenesis
can be composed.
Pathogenesis of Zika virus early in infection is extremely similar to Dengue virus.
During a mosquito blood meal, the virus is able to invade the body and infect
keratinocytes, fibroblasts, and Langerhans cells (45,46,47). Once initially viral
replication is successful viremia ensues and allows the virus to infect monocytes, which
allows for the virus to spread throughout the body (48). Utilizing a “Trojan horse”
methodology the infected monocytes are able to infiltrate immune privileged sites such
as the brain, testes, and placenta (49). Presently, there is no physiologically established
receptor for Zika viral infection. An attractive target that has shown promising results in
vitro is the AXL receptor. This receptor is a member of the TAM family which interacts
with Gas6 and Protein S which bind to the viral envelope (50). This receptor is
expressed on the early cells in which the virus infects such as keratinocytes and
endothelial cells (51, 52, 53). Even more promising is that AXL is also expressed on
neural progenitor cells and target cells within the testes (54, 55). These two tissue
tropism causes unique clinical manifestations. The first is the ability for the virus to infect
neural progenitor cells, once the virus is within the neuron viral replication ensues and
eventually induces apoptosis of the neuron. Continued viral replication results in major
tissue damage resulting in major neuronal developmental abnormalities. Describing the
clinical features of these outcomes is much more extensive. A large percentage (80%)
of Zika infections are asymptomatic. The mild form of the disease with clinical
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manifestations presents as a self-limiting febrile illness that lasts from 4-7 days. The
more severe form of Zika infection results primarily when the virus is transmitted in
utero. Microcephaly and Gullian-Barre syndrome rates were determined by Meta
analysis of 2.3% and 1.23% of all pregnancies respectively (56,57). Many more
neurological manifestations have been reported in Zika viral infections, these include
craniofacial disproportion, spasticity, seizures, brainstem dysfunction, and feeding
difficulties. More commonly than Microcephaly ocular abnormalities occur as a result of
Zika viral infection, these include focal pigment mottling, chorioretinal macular atrophy,
optic nerve abnormalities, cataract, intra-ocular calcifications, optic disk cupping, foveal
reflex loss, macular hypoplasia, and scarring (58). To combat Zika viral infection a
patients’ body first will induce an innate response. The early innate response is
centralized around pattern recognition receptors recognizing viral pathogen associated
molecular patterns. Most important of the early innate response is the stimulation of
type I and type III interferons. Type-I interferons will induce the JAK/STAT pathway
which allows for IRF9 to translocate to the nucleus and induce the expression of
interferon stimulated genes. Type-III interferons are critical to combating the virus at the
maternal fetal interface. The Adaptive immune response to Zika virus is very similar to
Dengue viral infection and poses the same immunological issues.
A critical event in both Dengue and Zika viral infection is the induction of antibody
dependent enhancement (ADE). The first description of ADE was by Halstead et al.
describing Murray Valley encephalitis virus where higher concentrations of antibody
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neutralized the virus on chicken embryo monolayer, but at lower concentrations the viral
titer increased to levels much greater than the viral control. Initially the type of Fc
receptor to which the antibody binds influences the effectiveness of the phagocytosis.
FcγRIIA is more highly expressed and has been most associated with ADE (59). Once
the antibody and receptor complex is formed a signaling cascade of ITAM molecules
are phosphorylated which recruit Syk/ZAP-70 to initiate phagocytosis (60). The amount
of antibody bound to the complex directly influences the amount of virus and the method
in which the complex is internalized. A smaller amount of antibody will utilize clathrin
mediated endocytosis to bring in a single viral particle. Larger amounts of antibodies will
induce aggregates and phagocytize via the mechanism previously stated bringing in a
larger amount of virus at one time (61). Once internalized the viral complex has the
ability to evade RIG-1 and MDA-5 both critical intracellular PRRs to induce type-I
interferons (62). The inhibition of these PRRs also dramatically alters the cytokine
profile of the infected cell, shifting from a pro inflammatory state to an anti-inflammatory
state (63, 64, 65, 66). Down stream of the RIG-1 and MDA-5 type-I interferons utilize
the Jak/STAT pathway to stimulate interferon stimulated genes that are potent antiviral
inhibitors. To overcome this the viruses, utilize NS5 to target the IFNAR for proteasomal
degradation (67) or to target STAT2 for degradation stopping the signaling cascade
(68,69). Cohort studies in Cuba and Taiwan indicate that patients with secondary DENV
infection had higher levels of serum IL-10 levels (70,71). In contrast to early in infection
which induces high levels of pro-inflammatory cytokines such as TNFα, IL-1β, and IL-6
10

secondary heterologous infection has demonstrated a slightly lower inflammatory
phenotype, which could be attributed to the induction of IL-10 (72). The cell type in
which the virus is infecting has significant effects on the amount of IL-10 induced.
Monocytes have been shown to induce high levels of IL-10 while macrophages are poor
inducers of IL-10 (66, 73). Once IL-10 is produced it decreases the production of IL-12
and IFNγ both of which are potent inducers of activating adaptive immune cells with
antiviral properties, must notably TH1 T cells and NK cells. Intracellular production of IL10 has been shown to increase the production of SOCS-3 which has been shown to be
a biological marker for severe dengue viral infection (62). In conjunction with the
immune modulation of the cells the viruses also influence other cellular functions
including autophagy. DENV and ZIKV have both demonstrated the ability to increase
autophagy and autophagasome formation in a Atg5 dependent manner (74, 75). This
process may involve NS4a up regulating autophagy utilizing the PI3 kinase pathway
(76).

Chapter II
Introduction Avian IgY
Utilizing avian derived antibodies as alternative immunotherapies has developed into an
attractive alternative for the treatment of animals and humans. Unique characteristics of
avian antibodies can partially be contributed to the way in which the avian immune

11

system differs from the mammalian system. Like the mammalian immune system, the
avian immune system possesses two major branches the innate and the adaptive
systems. The innate system is the earliest system activated in response to a pathogen
or antigenic stimuli. The innate response is made up of physical and chemical barriers
to initially halt invading pathogens. These barriers also include biochemical responses
such as defensins, complement, and lysozyme to name but a few. The innate system
also harbors coordinated recruitment of specialized cells such as macrophages,
granulocytes, thrombocytes, and natural killer cells. A distinct difference between
mammalian innate system and avian system is the avian system lacks neutrophils,
basophils, and eosinophils (77,78). Heterophils are the avian counterparts to the
mammalian neutrophils. Heterophils, like neutrophils, are the fast acting cells of the
innate system and are for the large part the first cell to the site of infection. Like
neutrophils heterophils have the ability to phagocytize invading pathogens. Heterophils
do not have the capabilities to produce an oxidative burst to destroy phagocytized
microbes, and the components of the granules contained within the cell differ from
mammalian neutrophils. Cellular receptors are also responsible for the innate immune
response. These class of receptors are term pattern recognition receptors (PRR)
because they interact with conserved pathogen-associated molecular patterns
(PAMPs). There are four primary classes of PRR, C-type lectins, TLRs, NLRs, and
RLRs. C-type lectins are responsible for recognize extracellular PAMPs, while NLRs
and RLRs are responsible for recognizing intracellular PAMPs. TLRs can recognize
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both classes of PAMPs and are one of the most widely studied PRR within the field of
avian immunology. Avian species possess TLR1/6/10, 2,3,4,5,7, and 8 which act
essentially as homologs to the mammalian counter parts (79-90). It is apparent that
chickens respond to the PAMP unmethylated CpG motif the classical TLR9 agonist, but
no evidence has been found for TLR9 expression (91-93). Chickens also possess two
unique TLRs 15 and 21 (94, 95). Studies have shown that S. enterica challenge
increased expression of chTLR15 specifically in the gut (95). Surprisingly chTLR21 has
been shown to respond to unmethylated DNA containing CpG motifs, which could be
the reason there has been no evidence of TLR9 in chickens because the function is
already dominate by chTLR21 (96,97).
Adaptive Immune system
To assist in the maturation and development of the adaptive immune system the avian
system possesses primary and secondary lymphoid organs. The primary lymphoid
organs include the thymus, bone marrow, and an organ unique to avian species the
Bursa of Fabricus (BF). The secondary organs include spleen, Harderian gland,
germinal centers and other lymphoid tissues. Avian T cells have many of the structure
and adaptive functions as mammalian T cells. Each T cell have a heterodimeric surface
receptor (TCR) that is composed of two immunoglobulin domains that undergo
extensive recombination to produce antigenic diversity (98). There are two heterodimer
clusters the TCRαβ or TCR γ∆. A distinction of avian maturation is that unlike
mammalian gene TCR clustering which is in one location avian species have two
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locations. The second location most resembles IgH V segments of mammals (99). A
second structural abnormality in the avian TCR development is the difference in CD3
expression. Mammals possess four CD3 subgroups while the avian species only have
two (100). To date TCR signaling of the avian system has no dissimilarities to the
mammalian system indicating that the lack of CD3 diversity and increased TCR diversity
does not influence downstream signaling drastically. The development of T cells
spatially within the avian host is remarkably similar to that of mammals. Naïve T cells
undergo development in the thymus. Differential expression in the periphery is dictated
by the rate in which the T cells enter they thymus for development. The γ∆T cells are
first to exit the thymus and circulate the periphery followed by the traditional αβT cells.
The development of avian B-cells is drastically different from that of the mammalian
system due to the presence of the BF. A common lymphoid progenitor cell expressing
CCRA+ undergo Ig rearrangement which are then transported by the blood to the BF
specially the mesenchyme (101, 102). Further Ig rearrangement and proliferation occurs
in the Bursal mesenchyme and it is suggested that surface Ig expression is needed for
the precursor cells to migrate to the Bursal follicles (103, 104). In order to remain in the
bursal follicles, the precursor B-cells must express AID and expression of CXCR5 to
bind to CXCL13. Gene conversion and a further round of proliferation occurs within the
follicles that is driven by BAFF (105, 106). Upon further maturation the bursal follicle
separates into the medulla and cortex. Upon antigen expression by a dendritic cell the
cells specific for that antigen then migrate to the follicular cortex (85,86). Once within
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the follicular cortex the antigen specific b cells undergo another round of gene
conversion and proliferation. At this point the B-cells are able to leave the bursa and
migrate to a secondary lymphoid organ such as the spleen. The B-cell can become
activated by exposure to the antigen in which they are specific for along with T-cell help
(107). After this point the antibody secretion process and plasma cell development is
indistinguishable from mammalian development (108, 109).

Immunoglobulin Maturation
The maturation in which antibodies of the avian adaptive immune system undergo
diverges significantly from their mammalian counter parts. There are three antibody
isotypes, IgM, IgA, and IgY present in the avian immune system. These isotypes are
mammalian homologs to IgM, IgA, and IgG (110). Antibody homologous to mammalian
IgE and IgD have been proposed, but the data is inconclusive on identification (111).
Avian IgY is distinguished from mammalian IgG due to the decay chain of the molecule
is larger and antigenically different from IgG, and at the genomic level IgY is more
similar to mammalian IgE than IgG (112). The structure of IgY is similar to IgG with two
light (L) and two heavy (H) chains. The molecular mass of IgY is slightly larger than IgG
167-250 kDa compared to 160 kDa respectively. The H chain has one variable (V)
region and four constant (C) regions. The L chain is composed of one (V) and one (C)
regions (113). Antibody diversity in the avian immune systems develops differently than
in the mammalian system. Loci rearrangements contribute slightly to diversity as both
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the H and L chain have only one V gene. A major mechanism of diversity of antibody
repertoire in the avian system is due to increased instances of somatic hyper
conversion (114, 115). The avian immune system has developed three additional
mechanisms to expand the antibody diversity: gene hyper conversion (115,116), V-J
flexible joining (117), and somatic point mutations (118). Gene hyper conversion occurs
in the BF, during which pseudo-V genes are processed and recombined into new
variable regions resulting in increased immunoglobulin diversity depending on where
the block of DNA from the V gene is spliced (119). This process is also applied to
pseudo-V(D) genes (120). These genes are considered pseudo genes because they
lack in promoter sequences necessary for transcription. (Reyanud CA). This unique
feature allows for antibody diversity equivalent to the VDJ & VJ rearrangement of the
mammalian system.
Biochemical Properties of IgY
Biochemically IgY is distinct from IgG partially due to the increased rigidity because of
the lack of hinge region in the C domain of the H chain. This changes the the
precipitation curve of IgY under high salt conditions (121). IgY is also more stable under
acidic conditions maintaining it’s functionality between pH 4.0-11.0 (122, 123). IgY
thermo satiability is comparable to IgG retaining functionality between 60-65ºC (122,
123). IgY is also more resistant to proteases which may allow it to retain functionality as
it passes through the stomach if orally administered (123, 124).
Advantages of IgY Immunotherapy
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There are distinct advantages to using IgY as an immunotherapy. The first is the
phylogenetic distance between avian and mammalian species. This distance means
that there is no cross-reactivity between IgY and mammalian IgG (125). This allows for
the production of antibodies generated against conserved mammalian proteins (126).
The phylogenetic distance also allows for greater antigenic recognition and affinity of
IgY than mammalian IgG. It has been demonstrated that chicken IgY will bind to porcine
antibodies with 3-5 times greater affinity than rabbit antibodies (126, 127). In a study
antibodies generated against E7 oncoprotein of human papillomavirus type 16 IgY
reacted against all of the peptides while IgG from rabbits recognized only two of the
eight (128). The use of avian egg yolk as a source for antibody production greatly
reduces the number of animals and strain on the animals. A single chicken yolk can
produce 100-200 mg of total IgY (129), with 2-10% of total IgY being antigenic specific
upon vaccination (130). IgY does not interact with mammalian complement systems,
which in the case of DENV infection is a positive attribute. A study demonstrated that
patients with Dengue hemorrhagic fever have elevated levels of activated complement
components specifically C3a and C5a (131). Another critical characteristic of IgY is the
lack of interaction with mammalian or known bacterial FcγR or Fc binding receptors. The
lack of interaction with Fc receptors leads to premise that IgY will not induce ADE when
encountering subsequent serotypes of Dengue or cross reactivity with ZIKV (134-137).
Finally, IgY does not react with rheumatoid factor or human anti-mouse IgG antibodies
(132, 133). This is important, because if the antibody reacts with the Fc part of
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mammalian IgG, which is typical of patients with rheumatoid arthritis, the amount of
antibody needed to neutralize the target antigen will be greatly increased.

General uses of IgY in virology
Due to the broader range of antigenic recognition and increased affinity to mammalian
antigens IgY has been implemented in the development of a number of diagnostic tests
and employed as immunotherapeutics. An enzyme-linked immunosorbent assay
(ELISA) was developed to detect severe acute respiratory syndrome-associated
coronavirus. This ELISA utilized IgY against the nucleocapsid protein as the detection
antibody to increase the sensitivity of the assay. When the nucleocapsid protein IgY
was compared directly against an IgG monoclonal antibody the detection limit of the
assay was increased dramatically from 20-200 pg/mL to 10 pg/mL (138). To increase
the power of IgY technology as a diagnostic tool for severe acute respiratory syndromeassociated coronavirus phage display generated monoclonal IgY antibodies with a
single-chain variable fragment. Using this phage display system monoclonal IgY
antibodies were generated against the spike protein which can be applied for rapid
diagnostics and can be applied therapeutically (139). The diagnostic capabilities of IgY
is also extended to hepatitis viruses. An indirect immunofluorescence assays was
developed using IgY as the primary antibody to recognize hepatitis A virus in frozen
liver sections (140). This technique is advantages because it is able to detect minute
amount of virus where IgM levels are too low to detect in the serum and the virus is
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unable to be detected by molecular means (141,142). The same anti-hepatitis IgY is
used is a immunoenzymatic assay to measure the total anti-hepatitis antibody levels.
This immunoenzymatic assay demonstrated increased sensitivity and specificity
compared to the commercially available kit. This test could potentially then be used in
place of the commercial kit or an alternative to the traditional IgG immunoassays. (143).
This same principal was extended to hepatitis B virus as well. The purification process
of the anti-hepatitis B virus was more extensive, but the resulting product could be used
as a secondary antibody in a rapid detection ELISA (144, 145). Another promising area
of assay development is utilizing IgY in immunochromatographic assays (ICAs). ICAs
are also called lateral flow dipstick immunoassays which are typically used for rapid
identification of a pathogen or substrate. Due to the short incubation time for these tests
they are commonly referred to as point of care tests as well. A ICA was developed for
canine parvovirus, which utilized a oligoclonal IgY preparation generated against canine
parvovirus virus-like particle. When the IgY ICA was compared with PCR identification
the ICA exhibited 94.17% conformity to the PCR results (146). Similar ICAs were also
developed against soft-shell turtle systemic septicemia spherical virus and swimming
crab reovirus (147, 148).
IgY as an Immunotherapeutic
Avian IgY has attracted considerable attention as an alternative to antibiotic therapy due
to the increasing rise of antibiotic resistant pathogens, specifically those which infect the
gastrointestinal tract. This trend hence has extended to viral pathogens of the
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gastrointestinal tract as well as systemic viral infections. One such example is the
production of anti-norovirus P particle to combat norovirus infection. The authors
demonstrated efficacy of their IgY preparation in vitro and suggested this could be used
as a passive immunotherapy for high risks groups such as young children and the
elderly (149). Building upon that study the production of a dual IgY preparation was
created to not only combat the P particle of norovirus, but also the VP8 spike protein of
rotavirus. The dual IgY preparation also demonstrated in vitro efficacy with NT50 of
0.25mg/ml for rotavirus and a blocking titer 50 (BT50) of 1: 1,300 for norovirus A and 1:
1,200 for norovirus B (150). Anti-rotavirus IgY has been utilized in newborn cattle which
dramatically reduced the viral shedding and severity of diarrhea compared to controls
(151, 152). A randomized double-blind clinical trial with 79 children with a history of
rotavirus induced diarrhea were treated with freeze dried egg yolk IgY or placebo, and
both groups received oral rehydration therapy. The group receiving IgY had significantly
reduced viral shedding and the stool output frequency was reduced, only 1 day after
treatment however (153). These results were mirrored in another clinical trial testing
Rotamix IgY, this trial the severity of diarrhea was also reduced in the treated group
compared to the placebo group. Viral shedding and oral hydration fluid administration
needed was decreased in the treated group (154). Goose derived IgY has
demonstrated efficacy against systemic viral infections. Goose derived IgY generated
against the DNA vaccine of hantavirus produced a robust humoral immune response
and the purified anti-hantavirus was able to protect Syrian hamsters from a lethal

20

challenge of hantavirus (155). In another study geese were immunized with inactivated
DENV2 and the humoral immune response was monitored. The subsequent IgY
preparation was then tested for it’s neutralization capacity in vitro and in vivo. The NT50
of the anti-DENV2 IgY was 2.5 µg/ml. Mice treated with anti-DENV2 IgY survived a
lethal challenge of DENV2 in a dose dependent manner with 1mg having 100% survival,
500µg 66%, and 50µg 33% survival (156). In each of these studies epitope mapping
was done on the newly developed IgY preparations and in each instance novel
antigenic epitopes were found in both viruses. This demonstrates the epitope diversity
that can be achieved utilizing the IgY platform. Upon further study enriching the IgY
preparations with novel epitopes could bring light to new neutralizing epitopes. It will
also allow for enrichment of IgY antibodies of known neutralization epitopes from
previously described monoclonal IgG panels. The previous studies demonstrate the
versatile and robust nature of utilizing IgY as not only a diagnostic tool, but also as an
alternative immunotherapeutic.
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Chapter III
Zika Virus Vector Competency
Abstract
Zika virus is an emerging arbovirus of humans in the western hemisphere. With its
potential spread into new geographical areas, it is important to define the vector
competence of native mosquito species. We tested the vector competency of Aedes
vexans (Meigen) from the Lake Agassiz Plain of northwestern Minnesota and
northeastern North Dakota. Aedes aegypti (L.) was used as a positive control for
comparison. Mosquitoes were fed blood containing Zika virus and 2 weeks later were
tested for viral infection and dissemination. Aedes vexans (n=60) were susceptible to
midgut infection (28% infection rate) but displayed a fairly restrictive midgut escape
barrier (3% dissemination rate). Co-fed Ae. aegypti (n=22) displayed significantly higher
rates of midgut infection (61%) and dissemination (22%). To test virus transmission,
mosquitoes were inoculated with virus and 16–17 d later, tested for their ability to
transmit virus into fluid-filled capillary tubes. Unexpectedly, the transmission rate was
significantly higher for Ae. vexans (34%, n=47) than for Ae. aegypti (5%, n=22). The
overall transmission potential for Ae. vexans to transmit Zika virus was 1%. Because of
its wide geographic distribution, often extreme abundance, and aggressive human biting
activity, Ae. vexans could serve as a potential vector for Zika virus in northern latitudes
where the conventional vectors, Ae. aegypti and Ae. albopictus Skuse, cannot survive.
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However, Zika virus is a primate virus and humans are the only amplifying host species
in northern latitudes. To serve as a vector of Zika virus, Ae. vexans must feed
repeatedly on humans. Defining the propensity of Ae. vexans to feed repeatedly on
humans will be key to understanding its role as a potential vector of Zika virus.

Introduction
Zika virus (family Flaviviridae) is a mosquito-borne virus of primates in sub-Saharan
Africa that has spread rapidly within the past decade to cause serious epidemics
throughout the western Pacific and Latin America (157). Several features of Zika virus
make its spread particularly troubling. In addition to being transmitted by infective
mosquitoes, Zika virus can also be transmitted sexually (158). No other arbovirus is
known to be sexually transmitted. In most cases, Zika virus infections in humans do not
produce life-threatening illness, but in some instances, Zika virus infections can lead to
a neuropathic condition known as Guillain-Barre´ syndrome, and in pregnant women,
Zika viral infection can infect the fetus causing a brain abnormality known as
microcephaly in the unborn child (159). Sylvatic circulation of Zika virus in Africa
involves primarily monkeys and several species of tree hole and container-breeding
Aedes spp., including Aedes africanus (Theobold) (160), Aedes luteocephalus
(Newstead), and Aedes vittatus Bigot (161) Urban circulation involves a human–
mosquito–human cycle with Aedes aegypti (L.) as the primary vector (162). Other
mosquito species have been implicated as competent vectors of Zika virus, most
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notably Aedes albopictus (Skuse) (163), and to a lesser extent, Aedes hensilli Farner
(164), and some (165) but not allstrains within the Culex pipiens L./Culex
quinquefasciatus Say complex (166-170). In this report, we tested Aedes vexans
(Meigen) from the upper Great Plains for their ability to transmit Zika virus. Figure 1
demonstrates the multi facet transmission cycles and how they are interconnected
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Materials and Methods
Mosquitoes
Host-seeking mosquitoes were collected using a Mosquito Magnet X trap (kind gift of
Metropolitan Mosquito Control District, St. Paul, MN) baited with bottled CO2 released at
a flow rate of ca. 500 ml per minute. The trap was operated overnight at rural residences
in Polk County, MN (31 July 206) and Grand Forks County, ND (22 September 2016).
Both sites are located within the Lake Agassiz Plain eco-region of northwestern
Minnesota and northeastern North Dakota. The next morning, the trap was transported
to the laboratory and mosquitoes were released into a large, cubic-meter screened cage.
Mosquitoes were maintained for several days on cotton pads soaked in 10% sugar water
and 0.05% antibiotic solution. Antibiotics were given to eliminate variation in bacterial
loads within the alimentary tracts of wild-caught mosquitoes and thus minimize any
potential confounding effects that midgut bacteria may exert on the infectivity of
experimentally administered virus (171). As a positive control for vector competence, an
Aedes aegypti colony (Costa Rica strain, F39) was established from eggs obtained from
BEI Resources. Female Ae. aegypti mosquitoes were likewise maintained for several
days on the glucose-antibiotic solution prior to testing.

Virus
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The strain of Zika virus used in this study was originally isolated from a patient in Puerto
Rico in 2016 (PRVABC59). Viral stocks were prepared after two passages of the isolation
onto Vero cells maintained at 37°C. Viral titer was estimated via a plaque assay, 10-fold
serial dilutions were inoculated onto Vero cells overlaid with 1% methylcellulose and
complete DMEM, which were then incubated for 7 days. The overlay was then removed
and the monolayer was fixed with 10% formaldehyde and stained with crystal violet.
Infection was measured by the observance of cytopathic effect and the resulting titer was
expressed as plaque-forming units per milliliter (PFU/ml). The viral stock was diluted 1:1
with heat inactivated fetal bovine serum then divided into 1 ml aliquots and stored at 80°C.

Oral infection of mosquitoes
Prior to infection, mosquitoes were transferred to 3.8-liter cylindrical cardboard cages (ca.
50 per cage) each fitted with a screened top secured with tape and a single high-security
double-layered dental dam access portal. Infectious blood consisted of Zika virus culture
media mixed 1:1 with de-fibrinated cow blood (Pel-Freez Biologicals, Rodgers, AK USA).
The first trial (Minnesota mosquitoes plus Ae. aegypti) used thawed virus fed to
mosquitoes at an estimated blood meal concentration 9.2 x 106 PFU/ml. The second trial
(North Dakota Ae. vexans) used fresh virus grown on Vero cells prior to mosquito feeding
and with an estimated blood meal concentration of 2.0 x 105 PFU/ml. Blood meals were
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administered via water-jacketed membrane feeders (circulating water at ca. 38°C) fitted
with de-salted pork sausage casing. Mosquitoes were given 1 hour to feed, after which
unfed mosquitoes were removed. Cages containing engorged mosquitoes were placed
within transparent plastic tubs and maintained on glucose-antibiotic solution for 14 days
in a biosafety level-2 insectary with restricted access and environmental settings at 28°C
and 16:8 L:D light cycle. At 14 days, mosquitoes were killed by freezing at -20°C for > 2
hours. For each mosquito, the legs were pulled off and the bodies (=infection) and
mosquito legs (=disseminated infection) were ground separately in 200 µl grinding
solution (M-199 + 5% calf serum + 0.5% antibiotics).

Parenteral infection and salivary transmission
Virus was inoculated into mosquitoes to test their ability to transmit virus orally.
Mosquitoes were immobilized by chilling (1 minute in -20°C freezer) in batches of 5 to 15
each and placed on a chill table (BioQuip, Rancho Dominguez, CA). Mosquitoes were
injected intrathoracically with 0.2 µl of media containing 1.8 x 107 PFU/mL using a glass
needle powered by a microinjection pump (TriTech Research Inc., Los Angeles CA).
Following injection, mosquitoes were placed into 0.5 liter cylindrical cardboard cages and
maintained as described above. On 16 to 17 days after injection, mosquitoes were tested
for their ability to secrete virus in their saliva (172). To do this, 3 to 5 mosquitoes at a
time were chilled, legs amputated and then placed on a strip of double-stick tape running
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along the edge of a glass plate. Mosquito were carefully positioned on the plate so that
their proboscises were free and hanging over the edge. Immediately after mosquitoes
were in position, a small amount of malathion insecticide (0.4 µl of 0.14%AI in acetone)
was applied to the thorax of each mosquito to stimulate salivation (173). After 10 to 15
minutes, this plate was abutted against a second glass plate to which capillary tubes
containing ca. 20 µl of M-199 media plus 10% calf serum were affixed. Each mosquito
proboscis was carefully inserted into a liquid-filled capillary tube and mosquitoes were
given 20 to 30 minutes to salivate during which they were examined periodically under a
stereoscope for probing behavior, salivation and ingestion of capillary tube contents.
After the allotted time, capillary tubes were collected and the contents expelled into
individual microfuge tubes containing 50 µl of media. Likewise, the mosquitoes were
removed and placed into individual microfuge tubes for processing. Tubes were labeled
so that expectorate samples could be matched to the individual mosquitoes from which
they had been collected.

Zika virus detection
Viral RNA was detected using reverse transcriptase polymerase chain reaction (RT-PCR)
techniques. Frozen triturates of mosquito bodies and legs were thawed, centrifuged at
14,500 rpm for 5 minutes and 140µL of supernatant was extracted for RNA using Qiagen
QIAamp Viral RNA Mini Kits according to manufacturer’s instructions. Real time PCR
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was conducted using Qiagen one-step RT-PCR kit with primers specific for the envelope
gene. Probe sequence:5’-56FAM/ACGCCTAAT/ZEN/TCACCAAGAGCGGAA/3IABkFQ3’

Primer1:

5’-TCCTAAGCTTCCAAAGCCTCCCAA-3’

and

Primer2:

5’-

TATCAGTGCATGGCTCCCAGCATA-3’. Cycle parameters were (i) 30 min at 50°C, (ii)
15 min at 95°C, (iii) 40 cycles of; 1 min at 94°C, 1 min at 54°C, 1 min at 72°C, and 10 min
72°C. Reactions were performed using CFX96™ IVD Real-Time PCR Systems and
accompanying software to determine cut-off values based on a minimum of 2 negative
controls (water only) and two positive controls (Zika viral culture extracts) per assay.

Results
Susceptibility to Oral Infection and Viral Dissemination
Membrane feeding success was higher for colonized Ae. aegypti (69%, n=39) than for
wild-caught Ae. vexans (43%, n=168; χ2 =8.82, P=0.003). Aedes aegypti had
significantly higher rates of viral infection and dissemination than Ae. vexans (Fisher
exact tests, P<0.024). Seventeen of 60 Ae. vexans tested (28%) became infected and
two (3%) developed disseminated infections, indicating a moderately severe midgut
escape barrier for Zika virus in this species. Eleven of 18 Ae. aegypti tested (61%)
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became infected and four (22%) developed disseminated infections (Figure 2).
However, the proportion of infected mosquitoes having disseminated infections did not
differ statistically between Ae. aegypti (4 of 11) and Ae. vexans (2 of 17; Figure 2;
Fisher exact test, P.0.14). Interestingly, there were no differences in infection or
dissemination rates between Ae. vexans fed fresh versus thawed virus (P’s>0.59,
Fisher exact tests), even though thawed virus had nearly 100-fold higher titer (Table 1).
This supports earlier findings that freshly cultured Zika virus is more infective to
mosquitoes than frozen virus that is thawed just prior to feeding to mosquitoes (174).
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Figure 2: Midgut and disseminated infection of Ae. vexans and Ae. aegypti.
A.) Percent midgut infection of Ae. vexans and Ae. aegypti mosquitoes exposed to
a blood meal containing Zika virus. B.) Percent disseminated infections from the
midgut of Ae. vexans and Ae. aegypti with midgut infections of Zika virus.
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%
%
%
Dissemination
a
b
c
Infection Dissemination
/ Infection

Mosquito
Origin

Virus and
Blood meal
Concentration

Aedes
aegypti

Colonized;
Costa Rica
strain (BEI
Resources)

Thawed
9.2 x 106
PFU/ml

61
(11/18)

22 (4/18)

36 (4/11)

Aedes
vexans

Wildcaught;
Grand
Forks Co.,
ND

Fresh
2.0 x 105
PFU/ml

28 (9/32)

3 (1/32)

11 (1/9)

Wildcaught;
Polk Co.,
MN

Thawed
9.2 x 106
PFU/ml

29 (8/28)

4 (1/28)

12 (1/8)

Aedes
trivittatus

Wildcaught;
Polk Co.,
MN

Thawed
9.2 x 106
PFU/ml

0 (0/6)

0 (0/6)

0 (0/0)

Culex
tarsalis

Wildcaught;
Polk Co.,
MN

Thawed
9.2 x 106
PFU/ml

0 (0/3)

0 (0/3)

0 (0/0)

Culiseta
inornata

Wildcaught;
Polk Co.,
MN

Thawed
9.2 x 106
PFU/ml

0 (0/1)

0 (0/1)

0 (0/0)

Mosquito
Species
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Table 1. Infection and dissemination of Zika virus in wild-caught and colonized
mosquitoes 14 days after ingesting defibrinated blood containing virus.
a

Percentage of mosquitoes containing virus in their bodies (number positive /
number tested).
b
Percentage of mosquitoes containing virus in their legs (number positive / number
tested).
c
Percentage of infected mosquitoes containing virus in their legs (number positive /
number tested).

Virus Transmission by Innoculated Mosquitoes
To test for salivary gland barriers, Ae. vexans and Ae. aegypti were inoculated with virus
and, after 16-17 days incubation, were stimulated to salivate into capillary tubes. When
the bodies of inoculated mosquitoes were assayed, all 47 inoculated Ae. vexans were
positive (100%) and 22 of 23 inoculated Ae. aegypti (96%) were positive. Saliva samples
were tested for virus from body-positive mosquitoes. Thirty-three of 47 body-positive Ae.
vexans (70%) were observed to either salivate or imbibe fluid during the salivation period,
whereas only 5 of the 22 body-positive Ae. aegypti (23%) were observed to do so.
Sixteen of the 47 Ae. vexans (34%) transmitted virus, whereas only one of the 22 Ae.
aegypti (5%) transmitted virus (Table 2) (Fisher exact test, p=0.06). Whether or not a
mosquito was observed to salivate into and/or imbibe fluid from its capillary tubes had no
bearing on whether or not virus was transmitted. Of the 16 Ae. vexans that transmitted
virus, 12 (75%) were observed to salivate and/or imbibe and 4 (25%) were not.
Conversely, of the 31 Ae. vexans that did not transmit virus, 21 (68%) were observed to
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salivate and/or imbibe and 10 (28%) were not (χ2=0.27, p=0.61). The single Ae. aegypti
that transmitted virus was not observed to salivate nor imbibe fluid. Thus stereoscopic
observation of mosquitoes during in vitro salivation tests was not useful in detecting actual
expectoration of saliva.
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Mosquito Species

a

Mosquito Origin

% Transmission

Aedes aegypti

Colonized; Costa Rica strain (BEI
Resources)

5 (1/22)

Aedes vexans

Wild-caught; Grand Forks Co., ND

34 (16/47)

Table 2. Transmission of Zika virus by mosquitoes 16 to 17 days after being inoculated
7
intrathoracically with 0.3 µl of media containing 1.8 x 10 plaque-forming units per
milliliter of virus.
a

Percentage of mosquitoes with a disseminated viral infection that expectorated virus
into fluid-filled capillary tubes following a topical application of 0.4 µl acetone
containing malathion (0.14% AI) to induce salivation.
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Discussion
This study indicates that Ae. vexans from the upper Great Plains is physiologically
capable of becoming orally infected and transmitting Zika virus. Aedes vexans displayed
moderate to severe midgut and midgut escape barriers to virus infection and
dissemination, respectively. However, once disseminated infections were established,
the transmission rate of Zika virus by Ae. vexans (34%, n.47) was comparable to
transmission rates reported at similar incubation periods (i.e., 14 d) for some (but not
all) strain combinations of Zika virus and Ae. aegypti (i.e., 175 [33%, n.12], 176 [21%,
n.14], 177 [42%, n.33], 178 [5%, n.189], 179 [31%, n.36]). Aedes vexans is the first
indigenous North American mosquito species found capable of transmitting Zika virus
under laboratory conditions. Several other mosquito species have been shown in
laboratory studies to be refractory to Zika virus, including Aedes triseriatus (Say) (Aliota
et al. 2016b), Aedes taeniorhynchus (Wiedemann) (170), and Culex tarsalis (Coq.)
(174) from North America, Aedes polynesiensis Marks from French Polynesia (177),
and Aedes notoscriptus (Skuse), Aedes procax (Skuse), Aedes vigilax (Skuse), Culex
annulirostris Skuse, and Culex sitiens Wiedemann from Australia (180). The primary
urban vectors of Zika are Ae. aegypti and Ae. albopictus. As Zika virus spread from
Africa into Asia, Oceania, and the Western Hemisphere, the virus encountered novel
populations and
strains of these vector species. It is now clear from recent vector competency studies
that the efficiencies by which Ae. aegypti and Ae. albopictus transmit Zika virus varies
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greatly depending on the strains of mosquito and virus examined. In our study, the rates
of viral infection (61%) and dissemination (22%) for Zika virus in our Ae. aegypti strain
were comparable to other strain combinations examined, yet the transmission rate (5%,
Table 2) was uncharacteristically low. We had purposely selected our “positive control
system”—i.e., a Latin American strain of Ae. aegypti (Costa Rica) and a Caribbean
isolate of Zika virus (Puerto Rico)—based on the assumption that the close geographic
proximity of origin between mosquito strain and virus isolate would result in optimal
virus transmission. This proved not to be the case. But this is not the first example of
incompatibility between geographically proximate strains. Interestingly, two separate
strains of Ae. aegypti from Senegal have been reported to have severely limiting midgut
escape barriers and insurmountable salivary gland barriers to the native Sengalese
strain of Zika virus (161). Thus, Ae. aegypti is probably not the vector for Zika virus in
Senegal. Conversely, a strain of Ae. aegypti from Mexico produced a significantly higher
rate of disseminated infection with a Zika virus strain from Senegal (60%, n.48) than
with Zika virus isolated from a patient in Puerto Rico (42%, n.48;
174). These studies indicate that the combination of mosquito and virus strains in the
Ae. aegypti–Zika system greatly influences vector competency although the outcome
cannot be predicted based on geographic origins of strains and isolates. Aedes aegypti
is widely distributed throughout tropical latitudes and analogously, Ae. vexans is widely
distributed throughout temperate and subarctic latitudes. Thus, it may be anticipated
that Ae. vexans may also display geographic heterogeneity in vector competence to
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Zika virus. Such heterogeneity has been shown to occur with Ae. vexans and Rift Valley
fever virus, where southern populations of North American Ae. vexans are susceptible
but northern populations are not
(181-183). Beyond its ability to transmit the virus, there are other characteristics of Ae.
vexans that could contribute to its role as a potential vector of Zika virus in the Northern
Hemisphere. First, Ae. vexans is an aggressive, nearly cosmopolitan Holarctic mosquito
species with a long flight range (184-186). It feeds primarily on large mammals and
readily attacks humans during both day and night (187). Second, Ae. vexans is
extremely prolific and often cited as the most abundant species found in mosquito
surveys conducted throughout the northern hemisphere, including central Canada
(188), most of the United States (189), France (190), Germany (191), Czech Republic
(192), Slovakia (193), Hungary (194), Croatia (195), Russia (196), Iran (197), South
Korea (198), and China (199). Third, Ae. vexans has been shown in laboratory studies
to be a competent vector for several arboviruses, including West Nile virus (200),
eastern equine encephalomyelitis virus (201), Saint Louis encephalitis virus (202), Rift
Valley fever virus (203), Tahyna virus (204), and Geta virus (205). Thus, it would seem
that Ae. vexans could potentially play a role in transmitting Zika virus if the virus were to
be introduced into more northerly latitudes of North America or Eurasia where the
primary vectors, Ae. aegypti and Ae. albopictus, are absent. On the other hand, Zika
virus is a virus of primates. Outside the tropics, humans are essentially the only
amplifying host. Thus, for Ae. vexans to be a vector of Zika virus in northern latitudes, it
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would have to feed on a viremic human, survive the extrinsic incubation period of the
virus, and then feed again on a human. Using mark–release–recapture techniques,
Jensen and Washino (1994) estimated the field survivorship of Ae. vexans in California
to be fairly low (daily survival.0.70) compared to typical values reported for Ae. aegypti
(e.g., 0.80 to 0.95). Low field survival would reduce the overall vectorial capacity of Ae.
vexans. Nevertheless, densities of host-seeking Ae. vexans can be extreme, even in
residential areas (206). Prodigious numbers may compensate for low daily survival and
weak vector competence, and thus elevate the importance of Ae. vexans as a vector for
zoonotic arboviruses in some regions (172). But again, the transmission pattern of Zika
virus in the north would undoubtedly be human-to mosquito-to-human. Thus,
information regarding the propensity of Ae. vexans to feed repeatedly on humans is key
in evaluating its potential as a vector of Zika virus. In the rural Midwest, Ae. vexans feed
primarily on deer (207). But the primary bloodmeal sources for Ae. vexans are less welldefined in suburban and urban areas where human density, and hence human
availability as blood sources, typically exceeds that of deer and other large mammals.
To help define the actual vector potential of Ae. vexans for Zika virus in North America,
mosquito surveillance programs could include pools of field-collected Ae. vexans as part
of their Zika virus testing— particularly in the southeast USA where Ae. vexans and Ae.
aegypti co-occur and the threat of local virus amplification exists. This may reveal
whether or not Ae. vexans mosquitoes are being naturally exposed to Zika virus.
Additional vector competence studies with Ae. vexans (e.g., comparing geographic
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strains, defining extrinsic incubation period, transovarial transmission, etc.) are
warranted because of this species’ expansive distribution, considerable dispersal
capability, often excessive abundance, and propensity to attack humans. Other
Holarctic anthropophagic mosquito species should also be examined.
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Chapter IV
Avian IgY as an Immunotherapy for Zika Virus
Abstract
Zika virus (ZIKV) is a newly emerged pathogen in the Western hemisphere. It was
declared a global health emergency by the World Health Organization in 2016. There
have been 223,477 confirmed cases including 3,720 congenital syndrome cases since
2015. ZIKV infection symptoms range from asymptomatic to Gullain-Barré syndrome
and extensive neuropathology in infected fetuses. Passive and active vaccines have
been unsuccessful in protecting from or treatment for ZIKV infection due to antibody
dependent enhancement (ADE). ADE causes an increased viral load due to increased
monocyte opsonization by non-neutralizing low avidity antibodies from a previous
dengue virus (DENV) infection or previous exposure to ZIKV. We have previously
demonstrated polyclonal avian IgY generated against whole-killed DENV-2 ameliorates
DENV infection in mice while not inducing ADE. This is likely due to the inability of the
Fc portion of IgY to bind to mammalian Fc receptors. We have shown here that ZIKV
oligoclonal IgY is able to neutralize the virus in vitro and in IFNAR-/- mice. The
concentration of ZIKV-specific IgY yielding 50% neutralization (NT50) was 25µg/mL.
Exposure of the ZIKV, prior to culture with ZIKV-specific IgY or 4G2 flavivirus envelope
IgG demonstrated that the ZIKV-specific IgY does not induce ADE. ZIKV IgY was
protective in vivo when administered following a lethal ZIKV challenge in a 3 week old
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IFNAR-/- mice. We propose polyclonal ZIKV-specific IgY may provide a viable passive
immunotherapeutic for ZIKV infection without inducing ADE.

Introduction
Flaviviruses are a major health concern throughout the world. A newly emerged
flavivirus that has major health implications is Zika virus (ZIKV). A majority of ZIKV
infections are asymptomatic in the host. Severe ZIKV symptoms extend to neurological
diseases including Gullian-Barre Syndrome (GBS) (208,209) and congenital Zika
syndrome (CZS). CZS can be further differentiated into microcephaly, brain
abnormalities, and other severe birth defects (210-214). In 2016 the world health
organization (WHO) declared ZIKV a world health threat and pushed for the
development of vaccines and antivirals to combat ZIKV infection (215).
ZIKV is a member of the Flaviviridae family which also includes dengue virus
(DENV), west nile virus (WENV), Japanese encephalitis virus (JEV), yellow fever virus
(YFV), and tick-borne encephalitis virus (TBEV). ZIKV is primarily spread by Aedes
species of mosquito (160). Recently our lab has identified that Aedes vexans is also a
potential competent vector which extends the geographical range of infection from
tropical to temperate climates as well (216). In the absence of quality vector control in
the countries affected by ZIKV the development of new antivirals and vaccine
candidates is required to control the spread of ZIKV.
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Severe flavivirus infection can be attributed to cross reactive inflammatory T cells
and non-neutralizing antibodies that induce antibody dependent enhancement (ADE)
(217,218). ADE occurs via antibodies from a primary infection binding to a heterotypic
flavivirus. The viral immune-complex is then recognized by the FcγR on a dendritic cell
or macrophage and binds via the Fc portion of the antibody. This complex is then
internalized in the endosome where the pH decreases as the endosome matures. This
drop in pH lowers the affinity of the antibody and virus allowing the virus to dissociate
from the antibody. Once the virus has dissociated from the antibody normal viral
replication is commenced by the fusion of the envelope to the membrane of the
endosome releasing the viral nucleic acid (219).
To date there is an unmet need for an effective antiviral therapeutic for ZIKV
infection. Recently, one area of research that is showing promising results is the
utilization of truncated antibodies that lack the Fc portion. Settler et al. demonstrated
that truncated monoclonal antibodies were able to neutralize primary ZIKV infection and
a secondary DENV infection without inducing ADE. They further go on to demonstrate
that the truncated monoclonal antibodies were able to protect IFNAR-/- mice challenged
with a lethal dose of ZIKV (219). We hypothesize that avian IgY, the avian homolog of
IgG, will be an effective therapeutic against flavivirus infections based on the unique
characteristic that full length IgY does not bind to mammalian FcγR. Previously we have
demonstrated that Dengue specific IgY was effective at neutralizing lethal infections
with DENV2 without inducing ADE (156).
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IgY is the avian homologue of mammalian IgG and shares characteristics with
mammalian IgG and IgE. IgY is the predominant isotype in sera after the initial
production of IgM, and is the primary antibody produced upon a secondary response
(110,111). IgY is found in two isoforms, in the serum of water fowl, full-length IgY that
contains two constant regions and an alternatively spliced IgY that lacks these two
constant regions (110,115). The alternatively spliced IgY would be the avian structural
equivalent of the truncated IgG proposed by Settler et al. Previous studies from our
laboratory have demonstrated the efficacy of the utilization of IgY in viral infections. We
first demonstrated that Andes virus-specific IgY provided protection from Hantavirus
pulmonary syndrome in a hamster model (155). Most recently we have demonstrated
that DENV specific IgY was able to protect AG129 mice from a lethal dose of DENV2
(156).
There are many benefits for the utilization of IgY as an immunotherapy in
mammals, first the phylogenic distance between the avian species producing the
antibody and the recipient mammalian host allows for a much broader range of
antigenic recognition. This is due to the increased avidity for mammalian antigens and
the ability to recognize antigens that normally would not be immunogenic in a
mammalian host. Increased antigenic recognition and avidity of IgY is attributed to the
unique antibody maturation process. During IgY maturation gene hyper conversion
allows for pseudo-V genes to recombine with existing variable regions of the Ig genes to
produce mature B-cells. The second reason is V-J flexible joining; this is when partial
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conversions of rearranged segments are replaced by pseudo-V(D) genes. The third
mechanism to produce diversity is the large amount of somatic hyper mutations that is
undergone (110-116). Another critical characteristic of IgY is the lack of interaction with
mammalian or known bacterial FcγR or Fc binding receptors. The lack of interaction with
Fc receptors leads to premise that IgY will not induce ADE when encountering
subsequent serotypes of Dengue or cross reactivity with ZIKV. Further, IgY does not
interact with mammalian complement systems, which in the case of DENV infection is a
positive attribute. A study demonstrated that patients with Dengue hemorrhagic fever
have elevated levels of activated complement components specifically C3a and C5a
(220). Not only are the immune characteristics of IgY attractive but the industrial
production potential also makes IgY an attractive therapeutic candidate. Due to the fact
that IgY can be isolated from the eggs of laying geese or hens, this allows for a noninvasive way of harvesting an immunotherapy compared to production in a mammalian
host such as rabbits. The antibody yield is also much greater per month due to this noninvasive aspect, 1,300 to 1,500 mg of IgY can be produced from one bird per month
compared to 200 mg from a mammalian source (221). There are currently large-scale
production methods and sites functional at this time making IgY an economically
feasible therapeutic.
In this study we demonstrate the efficacy of goose derived anti-ZIKV IgY in vitro
and in vivo. Specifically, ZIKV IgY produce protection greater than 50% reduction in a
plaque reduction neutralization test, and ZIKV IgY did not produce ADE in vitro. Finally,
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we demonstrate that ZIKV specific IgY can protect 3 week old IFNAR-/- mice from a
lethal ZIKV challenge.

Materials and Methods
Ethics Statement
Research was conducted in compliance with the Animal Welfare Act and adheres to the
recommendations in the Guide for the Care and Use of Laboratory Animals of the
National Institutes of Health. The protocol was approved by the Institutional Animal Care
and Use Committee at the University of North Dakota and the Institutional Biosafety
Committee.
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Geese
The geese (Anser domesticus 25 months old) used to produce IgY are an inbred hybrid
of a combination of German Embden, the Royal Chinese, and the Royal English breeds.
The animals were housed at the Specific Pathogen Free facility on the Schiltz Goose
Farm, Inc. The barn also housed a clean room for ISO egg production which was
equipped with HEPA filtration to remove circulating particles. Only authorized personnel
were allowed into the facility.

Mice
B6.129S2-Ifnar1tm1Agt/Mmjax (IFNAR-/-) were purchased from Jackson Laboratory
MMRRC stock #32045 (222). Mice were maintained in clean rooms in the Center for
Biomedical Research Center, UND.

Viruses and Cell Lines
Zika virus PRVABC59 was propagated in Vero cells (ATCC). Briefly Vero cells at 80%
confluency in 6 well plates were infected at an MOI of 0.1 and allowed to adhere for one
hour at 37ºC with 5% CO2. The cells were washed with DMEM containing 10% fetal
bovine serum (FBS) (Atlanta biologicals, Atlanta, GA), Penicillin/Streptomycin (Corning,
Corning, NY), and 2.5mM HEPES, (cDMEM). 3ml of cDMEM was replaced in the wells
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the plates were incubated at 37ºC 5% CO2 for five days. The cell supernatant was
centrifuged at 4,000x g for 5 min at 4 ºC to remove cell debris. The clarified cell
supernatant was diluted 1:2 in heat inactivated FBS and frozen at -80ºC. The resulting
viral stocks were quantified via plaque assay.

Vaccination
The vaccination schedule to produce DENV specific IgY was previously described. Zika
virus PRVABC59 was propagated in Vero cells to a titer of 3.8x105 PFU/ml. The cell
supernatant was centrifuged 4,000x g 10 min at 4 ºC to remove cell debris. The
resulting supernatant was exposed to 5.23 Mrad of gamma irradiation. The resulting
viral stock was shown to be inactivated via plaque assay quantification. Geese were
vaccinated with 1.52x105 PFU/ml of irradiated Zika virus. Dose was based on preirradiated viral titer. Immunizations consisted of 2 x 200 µl subcutaneous injections at
the back of the neck in two different injection spots. Eggs were collected starting from
week 6 after the first vaccination and stored at 4ºC until further use.

Purification of IgY from Goose Egg Yolk
Zika virus IgY was purified using polyethylene glycol. Briefly the egg yolk homogenate
was thawed and centrifuged at 10,000 x g for 30 min 4 ºC. The supernatant was passed
through a 0.2 µm sterile filter and concentrated using a 100 kDa (MilliporeSigma,
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Burlington, MA) tangential flow unit. 12% (weight/volume) of 6,000 MW PEG was added
to the concentrated supernatant that was then stirred for 30 min at room temperature.
The PEG mixture was then centrifuged at 10,000 x g for 30 min 4 ºC. The supernatant
was discarded and the pellet was resuspended to the original volume in 1x PBS. 12%
6,000 MW PEG was then added to the resuspended pellet and mixed for 30 min at
room temperature. The mixture was centrifuged at 10,000 x g for 30 min 4 ºC and the
pellet was saved. The pellet was resuspended in the original volume of 1x PBS (pH 7.4)
and concentrated to 50ml using 100 kDa cassette (MilliporeSigma) the final sample was
then diluted with 450ml of 1x PBS. Samples were additionally dialyzed in 1x PBS to
remove residual PEG.

Antibody Detection
The binding activity of flavivirus IgY was determined by ELISA as previously described
(155). Briefly 100 µl of antigen was coated onto a 96 well micro plate and stored
overnight at 4ºC. The following day the plate was washed 3x and then blocked with
400µl of blocking buffer and incubated at room temperature for 30 min. The wells were
washed three times and incubated with 100µl of IgY serially diluted 1:2 across the wells
of the plate. The plate was incubated at 37ºC for 30 min. The plate was washed 3x and
blocked at room temperature for 10 min. 100µl of biotinylated rabbit anti-goose IgY
antibody in blocking buffer was added to the plate and incubated at 37ºC for 30 min.
Following this, 100 µl of diluted strepavidin-HRP antibody in blocking buffer was added
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to each well, and the plates were incubated at 37°C for 30 min. Finally, the plate was
washed 3x and 100µl of o-phenylenediamine dihydrochloride color substrate was added
to each well and developed at room temperature protected from light for 15 min. The
reaction was stopped by adding 50µl of 1N H2SO4, and the absorbance was read in a
BioTek plate reader at A490. Data are represented as endpoint titers.

Plaque Assay
Vero cells were seeded into 6 well plates at 2x105 cells/well and allowed to come to
confluency. Viral stocks were thawed in a 37ºC water bath and diluted from 10-1 to 10-7
in cDMEM. Triplicate wells were infected with 250µl of viral dilutions whereas cell
controls were inoculated with media alone. Plates were placed at 37ºC, 5% CO2 for 1
hour lightly shaking every 15 min. The viral inoculum was removed, and the wells were
washed with 1x PBS. Next, 3ml of 1:1 of 2% methyl cellulose and cDMEM mixture was
added to each well. Plates were incubated for 7 days (ZIKV) and 10 days (DENV). At
the end of the incubation, the overlay was removed and the cells were fixed with 400 µl
of 10% formalin for 30 min at room temperature Formalin was removed and crystal
violet solution was added to each well for 10 min to stain the cell layer. The crystal violet
was removed and the wells were washed 3-5x with 1x PBS until plaques were clearly
visible.
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Plaque Reduction Neutralization
The plaque reduction neutralization assay (PRNT) is similar to the plaque assay noted
above with the following exceptions. The virus is diluted to 40-60 PFUs that is then
treated with IgY ranging in concentrations from 250 µg/ml to 3.125 µg/ml. Plaques are
then counted and a 50% or greater reduction of plaques was consider a significant
reduction (in accordance with WHO standards) (223).

Antibody Dependent Enhancement
The presence of ADE was assessed using the protocol in Diamond, et al. with minor
modifications (224). We used a MOI of 2 for ZIKV and 10 for DENV, due to the
difference in binding kinetics between ZIKV and DENV noted in Charles and
Christofferson (225). THP-1 cells were seeded at 1.76 x 104 cells/well for DENV
infection and 1.2 x 105 cells/well for ZIKV to accommodate for differences in titer of the
viral stocks. Antibody treatment was done with 300 ng of mAb 4G2 (Anti-flavivirus group
antigen antibody, Novus) 1 µg and 100 µg of anti-ZIKV IgY were incubated at 37ºC, 5%
CO2 for 1 hour prior to infection. Cells were infected for 90 min at 37ºC, 5% CO2. After
infection cells were centrifuged at 900 x g for 5 min and washed 3x. Cells were
suspended in cDMEM. Identical concentrations of the treatment antibody were added to
cells and incubated for four days at 37ºC, 5% CO2. Cells were centrifuged again and the
supernatant was collected and viral titer was determined by plaque assay.
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In vivo ZIKV-Specific IgY Protection
The therapeutic potential of ZIKV-specific IgY was tested using conditions that
cause 100% mortality in IFNAR-/- mice. 3 week old IFNRA-/- mice were challenged with a
lethal dose of ZIKV PRVABC59 (1.0x104 PFUs) intravenously (i.v.) via the retro-orbital
sinus. 24 and 48 hours after infection, mice were injected intraperitoneally with the
indicated amounts of ZIKV-specific IgY or control naïve IgY in a volume of 100 μL, or
100 μL of PBS as a negative control. Mice were observed twice daily for 14 days for
signs of morbidity and mortality.

Viral Load Quantification
At the mortality end point or conclusion of the study tissue samples (brain, spleen, and
liver) were processed for viral load. Briefly the tissues were collected in 1 mL of
cDMEM, and homogenated using a bullet blender. The supernatant was then
centrifuged at 4,500 x g for 10 min. The clarified supernatant was then diluted in
cDMEM in order to allow for 20-50 plaques per well in a 6 well plate. The plaque assay
protocol described above was then used to quantify viral load in the respective organs.
Viral copy number in the respective organs was also quantified via RT-qPCR. Viral RNA
was extracted from the clarified tissue supernatant with the Viral RNA mini kit (Qiagen,
Hilden, Germany). We then utilized Zika virus Genesig Easy kit (Genesig, Plymouth
Meeting, MA) to quantify the viral copy number of the infected organs.
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Epitope Mapping
Anti-ZIKV IgY epitopes were mapped using peptide arrays for E, prM, C, NS1, NS2a,
NS3, and NS5 proteins. 11 amino acid overlapping 15mer peptides were covalently
linked to a microarray slide (JPT Innovative Peptide Solutions, Mainz, Germany),
according to the manufacturer’s protocol. Briefly an uncoated slide and the slide
containing the microarray were gently laid upon one another separated by spacers. 50
µg/ml of control naïve IgY or anti-ZIKV specific IgY was incubated on the slides
overnight at 4ºC in a moist environment. Slides were then rinsed 5x with tris-buffered
saline and Tween20 (T-TBS) for 4 min, then 5x for 4 min with 18.5-ohm water. The
slides were then incubated with 1 µg/ml Cy5 goat anti-chicken IgY secondary antibody
(Abcam, Cambridge, UK) for 45 min protected from light. Slides were washed 5x with TTBS and 5x ultra-pure water, and dried with dust-free, oil free, canned air. A Genepix
4000 microarray reader was used to measure the fluorescent signal at a pixel size of 10
µm. The signal intensity mean values were calculated for each of the 3 sub-arrays and
corrected for background.

Statistical Analysis
Differences in PFU/ml and copy number between the antibody groups and controls as
well as the comparison of organ weights between groups were analyzed using ANOVA
with a Bonferroni post-test for multiple comparisons. Survival was measured using
Kaplan Meir and Mantel-Cox tests. The Mann-Whitney test was used to compare the
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difference in body weight percentages. GraphPad Prism (Version 7.0a, GraphPad
Sofware inc., CA) was used for statistical analysis with p values of < 0.05 considered
significant.

Results
Antibody characterization
The characterization of polyclonal anti-DENV2 has been demonstrated previously by
our lab [14]. Following the polyethylene glycol purification of anti-ZIKV IgY, SDS-PAGE
was used to verify the presence and purity of full length IgY and alternatively spliced
IgY. We were able to detect both full length and alternatively spliced forms of anti-ZIKV
IgY from the goose egg yolk homogenate (Fig. 3). An ELISA was then performed to
detect the presence of ZIKV specific IgY and to determine the endpoint titer of our IgY
preparation. The mean endpoint titer of the samples tested was 1:160,000.
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Fig. 3: Anti-ZIKV IgY purification: Purity of anti-ZIKV IgY after the second PEG
precipitation. Lane 1, supernatant from the PEG precipitation, lane 2, resuspended PEG
pellet. Lanes 3 and 4, molecular weight concentration and diafiltration. Lane 5,
molecular weight marker. Lane 6, control naïve IgY that was previously purified via
mercapto-ethyl pyridine HyperCel Hydrophobic Charged Induced Chromatograph for
comparison.
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In vitro viral neutralization and enhancement of Zika-specific IgY
Polyvalent anti-ZIKV IgY was purified from goose egg yolks that were tested for
neutralization capacity. Concentrations ranging from 250 µg/mL to 3.125 µg/mL were
utilized to determine the neutralization capacity of anti-ZIKV IgY. 40-50 PFUs of Zika
virus PRVABC59 was treated with anti-ZIKV IgY and then inoculated onto Vero cells to
determine the NT50. The concentration that yielded the NT50 was 25 µg/mL (Fig. 4a). To
determine if anti-ZIKV IgY induces ADE the experimental positive control Pan-flavivirus
IgG 4G2 antibody produced a productive viral replication cycle in THP-1 cells yielding a
significantly higher viral load compared to the untreated viral infection. The ZIKVspecific IgY did not enhance viral burden at any of the concentrations tested (Fig. 4b).
Cross reactivity and potential enhancement of a secondary Dengue virus infection was
also assessed as described above and no viral enhancement was demonstrated in a
DENV-2 infection of THP-1 cells.
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Fig. 4: Anti-ZIKV IgY neutralizes ZIKV in vitro without antibody-dependent
enhancement. A.) Anti-ZIKV IgY neutralized ZIKV infection in vitro with a NT50 of 25
µg/mL. B.) Purified anti-ZIKV IgY did not enhance infection in vitro when virus was
treated with 1µg/mL of IgY, whereas control 4G2 flavivirus IgG resulted in a significant
increase of infection. C.) Purified anti-ZIKV IgY did not enhance ZIKV infection in vitro at
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100 µg/mL. D.) Purified anti-ZIKV IgY did not enhance DENV2 infection in vitro at 100
µg/mL, where 4G2 flavivirus IgG significantly enhanced the viral load. ****p=<0.0001,
ns=not significant.

In vivo efficacy of ZIKV-specific IgY
IFNAR-/- mice were challenged with a lethal dose of ZIKV PRVABC59 (1x104 PFUs) and
the therapeutic potential of ZIKV-specific IgY was determined (Fig. 5). The results of
four independent experiments using a lethal dose of 1x104 PFUs were combined. Mice
receiving only PBS as a negative control succumbed to the infection by 6 days post
infection. An initial dose of 500 µg of ZIKV-specific IgY (n=6) 24 hours post infection
significantly extended the lifespan but did not allow for recovery from infection and all
mice succumbed to infection by day 7. 500 µg of ZIKV-specific IgY(n=7) administered
24 and 48 hours post infection lead to 85% therapeutic efficacy. This dose significantly
reduced infectious viral load and genomic viral copies in the brain, liver, and spleen
(Fig. 6). We achieved 100% therapeutic efficacy with 1 mg of ZIKV-specific IgY (n=6)
administered 24 and 48 hours post infection. This regimen resulted in sterilizing
immunity in all mice measured by infectious viral load and viral genomic copies (Fig. 6).
Naïve IgY was used as a control, two doses of 500 µg and 1 mg did extend the mice’s
lifespan but no subjects survived the challenge.
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Fig. 5: Therapeutic efficacy of anti-ZIKV IgY in vivo. 3 week old IFNAR-/mice were administered a lethal dose of ZIKV i.v. in 100 µL total volume. At 24 and 48
hour post infection mice were immunized i.p. with the indicated amount of antibody in a
volume of 100µL. Control mice were treated with 100 uL of PBS. Panels A and C
demonstrate the survival outcome of the treatments. B.) Weight was monitored daily
until day 14 or until morbid. Weights are reported as percent of starting weight, p-values
are denoted when comparing groups to viral control. **p<0.01, ***p<0.005, ****p<0.0001
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Fig. 6: Viral load reduction upon treatment with anti-ZIKV IgY. The viral load
reduction upon treatment with anti-ZIKV IgY: (A–C) The infectious viral load was
quantified in the brain (A), spleen (B), and liver (C) via a plaque assay. (D–F) The viral
genomic copy number was quantified in the brain (D), spleen (E), and liver (F) via RTqPCR. The viral load of the treated mice was compared to the viral control group. *p <
0.05, **p < 0.01, ***p < 0.005, ****p < 0.0001, and $ is the comparison to the matching
ZIKV-specific IgY group.

ZIKV-IgY Epitope Mapping
Epitope mapping was implemented to determine the specificity of the ZIKV specific IgY.
A pan-flavivirus microarray displaying overlapping linear epitopes of envelope (E),
membrane (M), peptide pr (PR) capsid protein (C), Non-structural proteins 1, 2, 3, and 5
(NS1, NS2A, NS3, NS5) reactivity was compared to negative control peptides MFI
average. Unbiased heat maps were generated in order to compare ZIKV-specific IgY to
control naïve IgY (Fig. 7). A majority of epitopes recognized by ZIKV-specific IgY were
centralized on the M and NS5 protein. ZIKV-specific IgY did recognize a known
neutralizing epitope on the E protein and a novel highly conserved NS1 epitope. We
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measured the potential cross reactivity of the polyclonal Zika specific IgY with other
flaviviruses via microarray analysis. We found significant cross reactivity with Dengue
virus, Yellow Fever virus, and West Nile virus (Fig. 8). The epitopes corresponding to
the number on the microarray are displayed in Table 2. The potential for cross
neutralization of these three viruses will be tested in the future.
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Fig. 7: Epitope mapping of structural and non-structural genes. A.) A heat map of
structural epitopes of Zika virus recognized by Zika specific IgY and naïve IgY. B.) A
heat map of non-structural epitopes of Zika virus recognized by Zika specific IgY and
naïve IgY. The strength of binding is indicated on a colorimetric scale with red being
strong binding affinity and green being no binding.
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Fig. 8: Epitope mapping of structural and non-structural genes. A.) A heat
map of structural epitopes of DENV recognized by Zika specific IgY and naïve IgY. B.)
A heat map of non-structural epitopes of DENV recognized by Zika specific IgY and
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naïve IgY. C.) A heat map of structural epitopes of WENV recognized by Zika specific
IgY and naïve IgY. D.) A heat map of non-structural epitopes of WENV recognized by
Zika specific IgY and naïve IgY. E.) A heat map of structural epitopes of YFV
recognized by Zika specific IgY and naïve IgY. F.) A heat map of non-structural epitopes
of YFV recognized by Zika specific IgY and naïve IgY The strength of binding is
indicated on a colorimetric scale with red being strong binding affinity and green being
no binding.
Position
Dengue Structural Proteins
Dengue Non-Structural Proteins
1 LEHGSCVTTMAKNKP
E
GTTVVVDEHCGNRGP
NS1
2 TAWDFGSLGGVFTSI
E
KAKIIGADVQNTTFI
NS1
3 QGEPSLNEEQDKRFV
E
ASAIQKAHEEGICGI
NS1
4 PLPWLPGADTQGSNW
E
FIIDGPNTPECPSAS
NS1
5 TTESRCPTQGEPSLN
E
MEIRPLSEKEENMVK
NS1
6 QKETLVTFKNPHAKK
E
GTTVVITENCGTRGP
NS1
7 LTLDCEPRSGIDFNE
E
MEIRPLSEKEENMVK
NS1
8 NIEAEPPFGESYIVI
E
LENLMWKQITPELNH
NS1
9 MAAILAYTIGTTHFQ
M
EKYQLAVTIMAILCV
NS2A
10 MAYMIGQTGIQRTVF
M
IAGVFFTFVLLLSGQ
NS2A
11 VEKVETWALRHPGFT
M
NQILEENVEVEIWTK
NS3
12 SVALVPHVGMGLETR
M
FRKRKLTIMDLHPGA
NS3
13 LFLAHAIGTSITQKG
M
TDGPERVILAGPIPV
NS3
14 IGQTGIQRTVFFVLM
M
PGSRDPFPQSNAPIM
NS3
15 SSEGAWKHAQRIETW
M
DAFPQSNAPIQDEER
NS3
16 VPHVGMGLETRTETW
M
TATPPGATDPFPQSN
NS3
17 FKTEDGVNMCTLMAM
Peptide_pr EDMLTVWNRVWIEDN
NS5
18 IDCWCNLTSTWVMYG
Peptide_pr GEGLHRLGYILEEID
NS5
19 EPRMIVGKNERGKSL
Peptide_pr DVFYLPPEKCDTLLC
NS5
20 CNLTSTWVMYGTCTQ
Peptide_pr LGEKWKSRLNALGKS
NS5
21 CPLLVNTEPEDIDCW
Peptide_pr YFHRRDLRLASNAIC
NS5
22 FKTTEGINKCTLIAM
Peptide_pr GDDCVVKPLDERFGT
NS5
23 RWGSFKKNGAIKVLR
C
HGSYEVKATGSASSM
NS5
24 AFITFLRVLSIPPTA
C
KKVTEVKGYTKGGPG
NS5
25 RKEIGRMLNILNGRK
C
DVFFIPPEKCDTLLC
NS5
26 PTAGILKRWGQLKKN
C
YILRDVSKKEGGAMY
NS5
27 LIGFRKEIGRMLNIL
C
YFHRRDLRLASMAIC
NS5
28 LAKRFSKGLLSGQGP
C
QVRSLIGNEEYTDYM
NS5
29 MNQRKKVVRPPFNML
C
QEEQGWTSASEAVND
NS5
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30
31
32
33
34
35
36
37

YILEEIDKKDGDLMY
KPTEQVDTLLCDIGE
DLENPHLPEKKITQW
LVKLHSGKDVFFIPP
CVVKPLDDRFASALT
SVWNRVWIEENPWME
SRKEFDLYKKSGITE
DVSKKEGGAMYADDT

Table 3: Corresponding epitopes to the heat maps of structural and nonstructural proteins of DENV recognized by anti-ZIKV IgY and naïve IgY.
Position
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22

West Nile Structural Proteins
VVFAILLLLVAPAYS
E
IDVKMMNMEAANLAE E
EFEEPHATKQSVIAL
E
SLTVQTHGESTLANK
M
QTHGESTLANKKGAW M
ESTLANKKGAWMDST M
KVMMTVNATDVTDVI Peptide_pr
CEDTITYECPVLAAG
Peptide_pr
ITYECPVLAAGNDPE
Peptide_pr
DVITIPTAAGKNLCI
Peptide_pr
ITYECPVLSAGNDPE
Peptide_pr
CEDTITYECPVLAAG
Peptide_pr
PEDIDCWCTKSSVYV
Peptide_pr
CPVLAAGNDPEDIDC
Peptide_pr
KSRAVNMLKRGMPRV C
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West Nile Non-Structural Proteins
ECPTQNRAWNSLEVE
NS1
NTLLKENGVDLSVVV
NS1
TRTTTESGKLITDWC
NS1
CDSKIIGTAVKNNMA
NS1
IIPITLAGPRSNHNR
NS1
TPQGLAKIIQKAHKE
NS1
VSRLEHQMWEAVKDE
NS1
VVDGPETKECPTQNR
NS1
EIDFDYCPGTTVTIS
NS1
ASTGVFNPMILAAGL
NS2A
LLVVFLATQEVLRKR
NS2A
KEKRSSAAKKKGACL
NS2A
FLELLRTADLPVWLA
NS3
PGAGKTRRILPQIIK
NS3
NPSQVGDEYCYGGHT
NS3
QRRGRIGRNPSQVGD
NS3
WLAYKVAAAGISYHD
NS3
SAIVQGERMEEPAPA
NS3
GRTTWSIHAGGEWMT
NS5
VVPCRGQDELIGRAR
NS5
RTWNYHGSYDVKPTG
NS5
KDIQEWKPSTGWYDW
NS5

NS5
NS5
NS5
NS5
NS5
NS5
NS5
NS5

23
24
25
26
27
28
29
30
31
32

AENIHVAINQVRSVI
ENEWMEDKTPVERWS
STGWYDWQQVPFCSN
VSRASGNVVHSVNMT
EEQNQWRSAREAVED
KNSGGGVEGLGLQKL
GKREDIWCGSLIGTR
HRRLARAIIELTYRH
IERLRREYSSTWHHD
YGWNIVTMKSGVDVF

NS5
NS5
NS5
NS5
NS5
NS5
NS5
NS5
NS5
NS5

Table 4: Corresponding epitopes to the heat maps of structural and nonstructural proteins of WENV recognized by anti-ZIKV IgY and naïve IgY.

Position
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16

Yellow Fever Structural Proteins
KGTTYGVCSKAFKFL
E
KVIMGVVLIWVGINT
E
FGGLSWITKVIMGVV
E
TALTIAYLVGSNMTQ
M
ERWLVRNPFFAVTAL
M
ERWLVRNPFFAATAL
M
VRNPFFAVTALTIAY
M
LQKIERWLVRNPFFA
M
VTLVRRNRWLLLNVT
Peptide_pr
YGKCDSAGRSRRSRR
Peptide_pr
YGKCDSAGRSRRSRR
Peptide_pr
CWCYGVENVRVAYGK Peptide_pr
REEPDDIDCWCYGVE
Peptide_pr
VTLVRKNRWLLLNVT
Peptide_pr
TLVRRNRWLLLNVTS
Peptide_pr
FSVGTGNCTTNILEA
Peptide_pr
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Yellow Fever Non-Structural
Proteins
WCCRSCTMPPVSFHG
NS1
AAVNGKKSAHGSPTF
NS1
AINFSKRELKCGDGI
NS1
NLVFSPGRKNGSFII
NS1
WKLEGRWDGEEEVQL
NS3
GKKLVPSWASVKEDL
NS3
WQVAKAGLKTNDRKW
NS3
EPTRVVNWEVIIMDE
NS3
VTRMAMTDTTPFGQQ
NS5
WHYCGSYVTRTSGSA
NS5
KVDTRAKDPPAGTRK
NS5
RTTWSIHGKGEWMTT
NS5
WRDVPYLTKRQDKLC
NS5
VSPGNGWMIKETACL
NS5
GGVEGIGLQYLGYVI
NS5
KGPLDRAAIEERVER
NS5

17
18
19
20
21

GLAVLRKVKRVVASL
QKTKQIGNRPGPSRG
WKMLDPRQGLAVLRK
WKMLDPRQGLAVLRK
FNILTGKKITAHLKR

C
C
C
C
C

CVVRPIDDRFGLALS
QDKTMVKEWRDVPYL
GKVDTGVAVSRGTAK
GKAYMDVISRRDQRG

NS5
NS5
NS5
NS5

Table 5: Corresponding epitopes to the heat maps of structural and nonstructural proteins of YFV recognized by anti-ZIKV IgY and naïve IgY.

Discussion
The results reported herein show that anti-ZIKV IgY purified from goose egg yolk has
the ability to neutralize ZIKV infection in vitro and in vivo without inducing ADE. We
observed therapeutic efficacy with 1 mg of anti-ZIKV IgY administered 24 and 48 hours
post infection in a lethal IFNAR-/- mouse model. Our results indicated that naïve IgY was
able to partially delay death in a lethally infected mouse but all mice immunized with
naïve IgY succumbed to infection. This is in contrast to previous data from our lab
demonstrating non-specific protection in a lethal DENV2 mouse infection model (156).
This may be due to unique structural features of ZIKV, the mature virion is more
thermally stable allowing for less dynamic rearrangement making the fusion loop on the
envelope protein more difficult to access (226,227). As indicated in Figure 1 there is a
full length and alternatively spliced form of IgY. All experiments performed here utilized
both the full length and alternatively spliced forms of IgY in our purified product. In the
future these distinct forms will be separated and the neutralization capacity of each will
be assessed.
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Epitope mapping was implemented to determine the specificity of the ZIKV
specific IgY and identify potential broad neutralizing epitopes. A pan-flavivirus
microarray displaying overlapping linear epitopes of envelope (E), membrane (M),
peptide pr (PR) capsid protein (C), Non structural proteins 1, 2, 3, and 5 (NS1, NS2A,
NS3, NS5) was compared to negative control peptides. The mean fluorescent intensity
of the negative control peptides was used to remove fluorescent signal from nonspecific binding. Unbiased heat maps were generated in order to compare ZIKV-specific
IgY to control naïve IgY (Figure 5). We found that the peptide LHGTVTVEVQYAGTD of
the IgG III like domain of the E protein was strongly recognized which is critical for cell
receptor binding as well as endosomal fusion. A NS1 epitope was a highly recognized
peptide, ESEKNDTWRLKRAHL, that is conserved across multiple strains of ZIKV. This
epitope has not been previously identified in other antibody screening studies. Future
studies are planned to isolate these epitope specific IgY populations and determine their
ability to neutralize ZIKV. We measured the potential cross reactivity of the polyclonal
Zika specific IgY with other flaviviruses via microarray analysis. We found significant
cross reactivity with Dengue virus, Yellow Fever virus, and West Nile virus (data not
shown). The potential for cross neutralization will be tested in the future.
Since the production of antivirals and vaccines may be difficult, alternative
therapies must be explored for emerging pathogens such as ZIKV. Avian IgY and egg
powder has been declared by the United States Code of Federal Regulation as
generally recognized as safe (GRAS) (228). The therapeutic potential of polyclonal
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avian antibodies has been demonstrated for a number of pathogens. Gastrointestinal
infections such as enterotoxic Escherichia coli, Salmonellal spp, Rotavirus, and
Helicobacter pylori have been successfully treated in mice and humans utilizing IgY
(229). IgY has also been implemented in Sweden as an orphan drug for the prevention
of Pseudomonas aeruginosa in cystic fibrosis patients (228). We recognize that
translating anti-ZIKV IgY to a human therapy will encounter challenges. It has been
previously demonstrated that pigs and mice will develop a humoral response to avian
IgY, notably the subclass IgG (229-231). Unpublished data from our lab demonstrated
weekly IgY injections begin to produce anti-IgY IgG in the third to fourth week of
immunizations. Purified IgY is unknown to have the ability to induce an allergic reaction
in humans. What has been demonstrated is that raw egg yolk, purified IgY, and
alternatively spliced IgY did not induce an IgE response in mice. Egg allergies are
important to consider when implementing IgY as a therapy in case residual egg yolk
lipids still remain in the purified product. Future allergenicity studies will need to be
conducted to definitively determine if purified IgY induces an allergic response or not.
At the present there are no FDA approved vaccines or therapies for ZIKV
infection. Multiple platforms; live attenuated, nucleic acid, vector, and peptide based,
have been employed to develop a safe efficacious vaccine for ZIKV (232-234). A major
conundrum for the development of a ZIKV vaccine is the risk of inducing ADE by a
subsequent DENV infection. Settler et al demonstrated that cross-reactive ZIKV
antibodies have the ability to enhance DENV infection (219). The severity of developing
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a therapy without properly assessing its ability to induce ADE was demonstrated by the
deployment of the tetravalent dengue vaccine that resulted in increased hospitalization
in younger and serum naïve individuals (235). This study emphasized the need to
produce vaccine and therapies for flaviviruses that do not induce ADE such as the case
of anti-ZIKV IgY demonstrated here. IgY is similar to aglycosylated IgG as IgY does not
bind to FcγR. IgY is advantageous because it does not require any genetic modification
or post production processing to prevent enhancement.
Teratogenic pathology induced by ZIKV when a mother is infected and the
infection spreads to the fetus is a major concern in the recent outbreak. Due to the
causal relationship between ZIKV and the development of microcephaly lead the WHO
to declare ZIKV a public health emergence and to expedite therapies needed to combat
ZIKV infection. Taking this statement into account future studies will examine the
therapeutic efficacy of immunizing dams with anti-ZIKV IgY and determining the
prevention of viremia of the fetus.
In summary, our studies comprehensively characterized the therapeutic potential
of anti-ZIKV IgY and demonstrated that IgY does not induce ADE. Our results indicate
that utilizing a polyethylene glycol extraction method obtained a highly pure IgY product.
Our purified anti-ZIKV IgY was able to inhibit ZIKV infection in vitro and did not induce
ADE at multiple concentrations. Anti-ZIKV IgY therapeutically administered to mice
protected against lethal ZIKV challenge. Epitope mapping demonstrated the recognition
of known neutralizing E epitopes as well as novel NS1 epitopes unique to avians. Thus,
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our study has addressed an important aspect of ZIKV infection, i.e., a safe and effective
immunotherapy that may be utilized in an epidemic outbreak of ZIKV.

Chapter V
Avian antibodies targeting dengue virus NS1 neutralize infection in
vitro and confer protection against lethal dengue disease in a mouse
model
Abstract
Dengue fever is caused by four dengue virus (DENV) serotypes (DENV1-4) and
is a continually increasing in global public health burden. A foremost challenge in
dengue vaccine and immunotherapy development is that cross reactive anti-DENV
antibodies can induce increased disease severity, via antibody dependent enhancement
(ADE). DENV nonstructural protein 1 (NS1) is an attractive immunotherapy target, as
antibody responses against this protein should not induce ADE. In this study, we
evaluated the ability of avian antibodies (IgY) targeting epitopes in NS1 to neutralize
DENV infection in vitro and in vivo. We characterized two unique anti-NS1 IgY
preparations which were capable of neutralizing DENV infection in vitro, similar to an
oligoclonal anti-DENV IgY preparation. Additionally, using ELISA we characterized the
binding specificity of these two anti-NS1 IgY isolates across all four dengue serotypes,
and established that they do not induce ADE in an in vitro system. We also
demonstrated that anti-NS1 IgY isolates did not block binding of soluble NS1 to
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endothelial cells to prevent the disruption of endothelial monolayers. Finally, we showed
that prophylactic treatment of mice with anti-NS1 IgY conferred significant protection
against lethal challenge with DENV2. Taken together, our findings highlight the potential
of anti-NS1 IgY antibodies as a promising prophylactic approach to prevent lethal DENV
infection.

Introduction
Dengue virus (DENV) is a mosquito-borne positive single strand mosquito-borne
RNA virus which is widespread in tropical and subtropical climates, and a significant
global public health burden. DENV causes approximately 390 million infections per
year, with 96 million will resultig in clinical disease and 500,000 patients requiring
hospitalization (236). The majority of dengue cases present as flu-like symptoms and
joint pain, known as dengue fever (DF). However, a subset of individuals develop more
severe forms of the disease, including dengue hemorrhagic fever (DHF) and dengue
shock syndrome (DSS). Severe DENV infection is characterized by increased vascular
leakage, which causes hypotension and circulatory collapse leading to shock and
potentially death (237).
The DENV nonstructural protein 1 (NS1) is a 48-55 kDa protein which induces
endothelial hyperpermeability in vitro and vascular leakage in vivo. NS1 is secreted from
DENV-infected cells and high levels of circulating NS1 in patients with severe dengue
disease has been observed (238). In mice, administration of NS1 and a sublethal dose
of DENV resulted in the production of pro-inflammatory cytokines TNFα and IL-6, as
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well as in lethal vascular leakage syndrome (239). Circulating NS1 is capable of binding
to the surface of endothelial cells in capillary beds (240). Further, interactions between
the endothelial glycocalyx layer (EGL) and NS1 result in the up regulation of sialidases
Neu1-3, which leads to the cleavage of sialic acid on the surface of the endothelial cells.
Binding of NS1 to the EGL also induces an increased expression of cathepsin L, which
in turn, over expresses heperanase and results in the cleavage of heparan sulfate and
heparan sulfate proteoglycans. Together, these processes result in EGL degradation
and loss of barrier integrity (241). Anti-NS1 antibodies capable of recognizing NS1 on
the surface of DENV-infected cells can trigger complement activation and complement
dependent cellular lysis (240). However, NS1 bound to uninfected cells can induce
similar mechanisms and result in increased vascular disruption (242,243). Intracellular
expression of NS1 is critical in the formation of viral replication complexes in the
endoplasmic reticulum (ER) and deletion of NS1 halts viral replication (244-246).
Indeed, NS1 co-localizes with viral RNA, as well as other non-structural proteins, to help
stabilize the viral replication complex within the ER lumen. It has also been
demonstrated that NS1 co-localizes with the structural E and prM proteins, which
indicates that NS1 is involved in trafficking of mature virions to the cell membrane for
efficient viral budding (247). Therefore, given the role of NS1 in the pathogenesis of
severe dengue disease, and its functions in immune evasion and viral replication, it is
reasoned that NS1 blockade could result in an effective therapeutic.
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Due to the challenges of developing an effective and safe vaccination for DENV
alternative antiviral therapies need to be explored. IgY is the avian homologue of
mammalian IgG and shares characteristics with mammalian IgG and IgE. IgY is the
predominant isotype in sera after the initial production of IgM and is the primary
antibody produced upon a secondary response (110,111). IgY is found in two isoforms
in the serum of water-fowl; full-length IgY, which contains two constant regions and an
alternatively spliced IgY, which lacks these two constant regions (125). Due to the
phylogenetic distance between avian and mammalian species, a much broader range of
epitope recognition and higher binding affinities are achieved, which allows for novel
epitopes to be recognized (126,129). IgY comprises 75% of all immunoglobulins in
avian hosts with concentrations of 5 mg/ml in serum (129). IgY has been utilized to treat
human pathogens such as H. pylori, S. mutans, S. sobrinus, P. gingivalis, Rotavirus,
and P. aeruginosa in Cystic fibrosis patients (227-230). An attractive characteristic of
IgY for flavivirus infection is that IgY does not interact with mammalian FcγR, which
eliminates the risk of ADE. This is critical for developing immunotherapies for DENV
infection. Another unique characteristic of IgY is that it does not interact with the
mammalian complement system, thus preventing off-target effects of anti-NS1
antibodies by triggering lysis of non-infected cells (131). We employed the neutralization
capabilities of IgY to non-structural protein 1 of DENV2.
We previously demonstrated that avian IgY is effective at neutralizing DENV2
infection in vitro and in vivo without inducing antibody dependent enhancement (ADE)
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(156). Epitope mapping of a polyclonal anti-DENV IgY preparation revealed the
presence of antibodies specific against NS1 epitopes. We hypothesized that these
antibodies could neutralize NS1-induced pathology and be protective in a mouse DENV
challenge model. We found that 2 IgY antibody preparations, denoted NS1-1 and NS18, were effective at neutralizing the virus in vitro. However, these avian antibodies did
not prevent soluble NS1 from binding to endothelial cells or limit endothelial permeability
in vitro. Finally, passive transfer of NS1-specific IgY antibodies into interferon-α/β
receptor-deficient C57BL/6 (Ifnar-/-) mice conferred significant protection against DENVinduced morbidity and mortality.

Materials and Methods
Ethics statement
Experimental procedures involving the use of animals were conducted in compliance
with the Animal Welfare Act and in adherence to the recommendations in the Guide for
the Care and Use of Laboratory Animals of the National Institutes of Health. All
experiments were approved and performed according to the guidelines of the
Institutional Animal Care and Use Committee of the University of California, Berkeley.

76

Epitope specific IgY isolation
Peptides 15 amino acids in length were produced by JPT Innovative Peptide Solutions
for NS1 of DENV2. Utilizing AminoLink Plus Immobilization Kit (Thermo Scientific) IgY
was isolated for specific epitopes. The protein was coupled to the AminoLink column
according to the manufacture’s instructions. Briefly, the AminoLink Plus resin was
resuspended and washed twice with pH 10 Coupling Buffer. Two ml of a 1.5 mg/ml of
peptide solution specific for the epitope of interest were added to the column and was
rocked end over end overnight. The column was centrifuged and washed with 2ml of
Quenching Buffer twice. Two ml of Quenching Buffer were added and column were
rocked for 30 minutes. The Quenching Buffer was then removed and the column
washed four times with 1X PBS. Two ml of 6.9 mg/ml of DENV2 oligoclonal IgY were
added to the column with 200 µl of Binding Buffer. The column was rocked end over
end for one hour. The sample was removed and 1 ml of Binding Buffer was added and
eluted into the same tube as the sample. Column was washed three times with 1x PBS
and antibodies were eluted with 2 ml of Elution Buffer three times. A Coomassie Plus
Assay Kit (Thermo Scientific Waltham, MA) was used to quantify the protein after
elution. The microplate procedure was followed according to manufacture’s instructions.

Viruses and cell lines
DENV-2 VR-1584 and Zika virus PRVABC59 were propagated in Vero cells [American
Type Culture Collection (ATCC)]. Briefly, Vero cells at 80% confluency in 6 well plates
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were infected at an MOI of 0.1 and allowed to adhere for one hour at 37ºC 5% CO2. The
cells were washed with DMEM containing 10% fetal bovine serum (FBS) (Atlanta
biologicals, Atlanta, GA), Penicillin/Streptomycin (Corning, Corning, NY), and 2.5mM
HEPES, (cDMEM). Three ml of cDMEM were replaced in the wells and the plates were
incubated at 37ºC 5% CO2 for 5 days. The cell supernatant was centrifuged at 4,000 x
g for 5 minutes to remove cell debris. The clarified cell supernatant was diluted 1:2 in
heat inactivated fetal bovine serum and frozen at -80ºC. DENV2 D220 was generated
from the parental strain DENV2 PL046 (247). The virus was propagated in Aedes
albopictus C6/36 cell line (ATCC) and titered by plaque assays using baby hamster
kidney (BHK) cells.

Mice
Interferon-α/β receptor–deficient C57BL/6 (Ifnar−/−) mice were bred and housed in
specific pathogen-free conditions at the University of California, Berkeley Animal
Facility. Five- to 8-week-old male and female mice were used for all experimental
procedures.

Lactate dehydrogenase assay
Vero cells were seeded into 6 well plates at 2x105 cells/well. DENV2 was treated with
25 µg of anti-NS1 IgY, control naïve IgY, and oligoclonal DENV IgY, and incubated for 1
hour at 37ºC 5% CO2. Cells were then infected with 250 µl (MOI 0.1) and incubated for 1
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hour at 37ºC 5% CO2. Viral inoculum was removed and cells were refed with cDMEM
and incubated for 5 days at 37ºC 5% CO2. Cell supernatants were removed and a
Pierce LDH Cytotoxicity Assay Kit (Thermo Scientific, Rockford, IL) was utilized to
determine cytotoxicity per the manufacture’s instructions.

Plaque assay
Vero cells were seeded into 6 well plates at 2x105 cells/well. The cells were incubated
37ºC 5% CO2 and were allowed to come to confluency. Viral stocks were thawed in a
37ºC water bath and diluted from 10-1 to 10-7 in cDMEM. Wells were infected with 250 µl
of viral dilutions in triplicate also cell controls were inoculated with media alone. Plates
were placed at 37ºC 5% CO2 for 1 hour lightly shaking every 15 minutes. Viral inoculum
was removed and the wells were washed with 1X PBS. Next, 3ml of 1:1 of 2% methyl
cellulose and cDMEM were added to each well and the plates were incubated for 10
days (DENV) and 7 days (ZIKV). At the end of the incubation the overlay was removed
and 400µl of 10% formalin were added to each well and incubated for 30 minutes at
room temperature to fix the samples. Finally, the formalin was removed and crystal
violet solution was added to each well for 10 minutes to stain the cell layer. The crystal
violet was removed and the wells were washed 3-5 times with 1x PBS until plaques
were clearly visible.

Neutralization assays
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Neutralization assays were used to evaluate the ability of anti-NS1 IgY antibodies to
block DENV infection in vitro. In brief, IgY antibodies were diluted to a starting
concentration of 0.1 mg/mL. Ten 4-fold dilutions were mixed with equivalent volumes of
DENV2 D220 for 1 hour before infecting U937 DC-SIGN cells, a DENV-permissive
human monocytic cell line (248). Two hours following infection, cells were washed, and
then fixed and stained for DENV E protein using 4G2 mAb-Alexa 488 24 hours later.
The percentage of infected cells was calculated using a Guava flow cytometer (EMD
Millipore) by gating Alexa 488-positive cells. The antibody dilution that reduced DENV
infection by 50% (50% neutralizing antibody titer [NT50]) was calculated using Prism
software (GraphPad).

Antibody dependent enhancement
ADE was assessed by co-incubating virus (MOI of 1) and antibody solutions for 1 hour
at 37ºC 5% CO2 then added to 2x105 K562 cells/well and incubated for 1 hour under
same conditions. Cells were then washed with 100 µl of cDMEM and maintained for 2
days at 37ºC 5% CO2. Cells were fixed with 10% formalin for 30 min at room
temperature. Cells were subsequently washed with FACS buffer and with flow
cytometry perm buffer (TONBO, San Diego, CA) and stained with 4G2 mAb-Alexa 488
conjugated antibody (Anti-flavivirus group antigen antibody, Novus Centennial, CO).
Once stained and washed, the cells were analyzed via FACS and the number of Alexa
488 positive cells were calculated (225).
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ELISA
Binding of IgY antibodies to the 4 DENV NS1 serotypes (DENV1, Nauru/Western
Pacific/1974; DENV2, Thailand/16681/84; DENV3, Sri Lanka D3/H/IMTSSA-SRI/
2000/1266); and DENV4, Dominica/814669/1981) was evaluated by ELISA. Briefly,
MaxiSorp® ELISA plates (Thermo Scientific Nunc) were coated with 50 μl of NS1 (The
Native Antigen Company) (0.5 μg/ml) and incubated overnight at room temperature.
After blocking with 1% BSA in PBS (1% BSA-PBS), wells were incubated for 1 hour at
room temperature with anti-NS1 IgY antibodies. Plates were then washed and
incubated for 1 hour at room temperature with horse radish peroxidase-labeled goat
anti-chicken IgY (abcam) at 0.5 μg/ml in 1% BSA-PBS. The assay was developed using
an ABTS-HRP substrate kit (SeraCare), according to the manufacturer’s specifications.

NS1 binding assay
A recently developed NS1 binding assay were used to determine if anti-NS1 IgY
antibodies could prevent binding of NS1 to FreeStyle 293F suspension cells (Thermo
Fisher Scientific) [Puerta-Guardo et al. 2019 Cell Rep.]. Briefly, eight 3-fold IgY antibody
dilutions were mixed in 96-well tissue culture plates with recombinant His-tagged
DENV2 NS1 (10 ug/ml) and incubated for 30 min using gentle oscillation. A suspension
of 5 x 104 293F cells was then added to each well and incubated for 45 min at 37°C,
5%C02. Finally, an AlexaFluor 647-conjugated anti-His-tag antibody (mAb-A647) was
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used to detect NS1 bound to the surface of 293F cells, and samples were analyzed by
flow cytometry.

Trans-endothelial electrical resistance (TEER) assay

To determine if anti-NS1 igY antibodies could prevent NS1-induced endothelial
hyperpermeability, human pulmonary microvascular endothelial cell (HPMEC)
monolayers grown on a 24-well Transwell polycarbonate membrane system (Transwell
permeable support, 0.4 mM, 6.5-mm insert; Corning Inc.) were incubated with NS1 (5
µg/ml) and IgY antibodies. Endothelial permeability was evaluated by measuring TEER
in ohms at sequential 2-h time points. Measurements were performed using an
epithelial voltohmmeter with “chopstick” electrodes (World Precision Instruments).
Transwell inserts containing untreated HPMEC cells were used as a negative control
and inserts with medium alone were used for blank resistance measurements. Relative
TEER was expressed as the ratio of resistance value as follows: [ohm(experimental
condition) − ohm (medium alone)]/[ohm (nontreated endothelial cells) − ohm (medium
alone)]. After 24 h of treatment, 50%of upper and lower chamber media was replaced
by fresh endothelial cell medium.

Dengue virus challenge experiments
To evaluate the protective capacity of anti-NS1 IgY antibodies, mice were injected
intraperitoneally (i.p.) with 5 µg of 4G2 mAb and 150 µg of IgY antibodies. Twenty-four
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hours later, mice were infected with 3 x105 PFU of DENV2 D220 by intravenous (i.v.) tail
vein injection. Mice were monitored for 10 days and scored for morbidity and mortality
using a standardized 5-point system (249).

Results
Neutralization capacity of anti-DENV2 NS1 in vitro.
Epitope anti-DENV2 NS1 IgY was column purified from the oligoclonal anti-DENV IgY
stock. Each epitope was given a number ranging from 1-8 to denote a particular amino
acid sequence. To assess potential candidates for further neutralization analysis each
anti-DENV2 NS1 preparation was tested for inhibition of DENV-induced cellular
cytotoxicity (Fig. 9A). Candidates that demonstrated a significant reduction in cellular
cytotoxicity were then assayed for neutralization capacity via plaque reduction
neutralization tests. Concentrations ranging from 100 µg/mL to 3.125 µg/mL were
administered to determine the 50% neutralization titer (NT50). In these experiments, the
NT50 of NS1-1 estimated at was 3.125 µg/mL while NS1-8 was 6.25 µg/mL (Fig. 9B-C).
In adition, using a flow cytometry-based neutralization assay the NT50 of NS1-1 and
NS1-1 were 1.2 µg/mL and 1.6 µg/mL, respectively (Fig. 9D).
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Anti-DENV2 NS1 IgY binds NS1 from multiple DENV serotypes
Each of the anti-DENV2 NS1 IgY preparations that demonstrated significant
neutralization were assessed by ELISA for their ability to bind to NS1 from the 4 DENV
serotypes. NS1-1 was capable of binding to the 4 DENV NS1 serotypes at higher
concentrations, but showed a higher affinity for DENV2 NS1 and DENV 3 (Fig. 10A). A
similar trend was observed for NS1-8 (Fig. 10B). Higher concentrations of naïve IgY
bound non-specifically to serotypes DENV2 NS1, DENV3 NS1, and DENV4 (Fig. 10C).
This data demonstrates a broad recognition of multiple serotypes of DENV NS1 by antiNS1 IgY antibodies with a preference DENV2 NS1, the serotype used to immunize
geese for IgY production.

85

A.)

B.)

OD (450 nm)

OD (450 nm)

DV1 NS1

3

DV2 NS1
DV3 NS1

2

DV4 NS1

1
0

2

1

0

-1

IgY NS1-8

4

-2

-3

DV1 NS1

3

DV2 NS1
DV3 NS1

2

DV4 NS1

1
0

2

Log Antibody Concentration (ug/ml)

1

0

-1

Naive IgY

4

OD (450 nm)

IgY NS1-1

4

C.)

-2

Log Antibody Concentration (ug/ml)

-3

DV1 NS1

3

DV2 NS1
DV3 NS1

2

DV4 NS1

1
0

2

1

0

Fig. 10: Anti-NS1 binding to DENV NS1. NS1-1 (A.) NS1-8 (B) and naïve (C) IgY
antibodies were serially diluted and binding to NS1 protein from each of the four
serotypes was measured by ELISA.

86

-1

-2

Log Antibody Concentration (ug/ml)

-3

Anti-DENV2 NS1 IgY does not induce ADE of DENV or ZIKV
As NS1 is not a structural protein, anti-NS1 should not facilitate ADE of mature virions.
To test this, we utilized the bone marrow lymphoblast cell line K562 which are not
permissive to flaviviral infection except via the FcR, to determine if anti-NS1 Igy
antibodies could mediate ADE. As measured via FACs. NS1-1 and NS1-8 did not
enhance either DENV infection or ZIKV infection of K562 cells (Fig. 11A-B).
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infect K562 cells. The 4G2 mAb, specific for the flavivirus envelope protein, was used
as a positive control.

Anti-DENV NS1 IgY antibodies do not inhibit NS1 cell binding or NS1induced endothelial permeability
To address if our anti-DENV NS1 IgY antibodies can prevent NS1 cell binding, each of
the anti-IgY preparations were incubated with soluble NS1 and then added to 293F
cells. At the tested concentartions, NS1-1 and NS1-8 were unable to inhibit NS1 binding
to 293F cells (Fig. 12A). Further, we used a TEER assay to evaluate the ability of antiNS1 IgY antibodies to prevent NS1-induced endothelial barrier dysfunction of HPMECs.
In these experiments, NS1-1 and NS1-8 were unable to prevent the loss of electrical
resistance due to increased endothelial permeability (Fig. 12B-E).
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Fig. 12: Soluble NS1 binding and TEER assays: A.) NS1 binding to the surface of
293F cells in the presence of anti-NS1 IgY antibodies was measured by flow cytometry.
An anti-His-tag antibody (mAb-A647) was used to detect NS1 bound to the surface of
293F cells. The mouse monoclonal antibody (mAb) 2B7, specific for NS1, was used as
a positive control. B.) HPMECs were grown on Transwell semi-permeable membranes
(0.4 mm pore size), and DENV2 NS1 protein (5 µg/mL, 1.5 ug total protein) in
combination with IgY antibodies or controls were added to the apical chamber. A TEER
assay was used to assess the effect of IgY antibodies on NS1-induced endothelial
permeability at indicated time-points over 48 h. Naïve IgY was unable to block soluble
NS1 from inducing loss of electrical resistance in the endothelial monolayer. C.) 2B7
was able to inhibit the decrease in electrical resistance of the endothelial monolayer
caused by soluble NS1. D.) NS1-1 IgY was unable to block soluble NS1 from inducing
loss of electrical resistance in the endothelial monolayer. E.) NS1-8 IgY was unable to
block soluble NS1 from inducing loss of electrical resistance in the endothelial
monolayer.

In vivo efficacy of Anti-DENV NS1 IgY
To determine if anti-NS1 IgY antibodies could protect against DENV-induced morbidity
and mortality, Ifnar-/- mice were prophylactically treated with 150 µg of anti-DENV2 NS1
IgY antibodies or naïve IgY. Twenty-four hours post treatment, mice were challenged
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with 3 x 105 PFU of DENV2 D220 using ADE conditions and morbidity and mortality
were monitored for 10 days. Notably, none of the mice treated with NS1-8 IgY showed
signs of morbidity or succumbed due to DENV infection (Fig 13 A). However, survival
among Ns1-1 IgY-treated mice was only 50%, while only 25% of the animals treated
with naïve IgY or PBS did not succumb upon DENV challenge (Fig 13 B).
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Fig. 13: Passive transfer of anti-NS1 IgY antibodies decreases DENV-induced
morbidity and mortality in Ifnar-/- mice. IgY antibodies (150 µg) were passively
transferred into Ifnar-/- mice and, 24 hours later, challenged i.v. with lethal antibodyenhanced DENV2 D220 infection. (A) Signs of DENV-induced morbidity were recorded
daily for 10 days. The proportion of each group of mice displaying the indicated signs is
shown. (B) A Kaplan–Meier survival curve is shown. Animals treated with anti-NS1 IgY
antibodies were significantly protected compared to Naïve IgY or PBS-treated controls.

Discussion
Several groups have created monoclonal antibodies to DENV NS1 protein. A
majority of these antibodies target the wing domain, which enables the antibody to bind
to the hexameric NS1 lipid complex structure preventing the pathology induced by
soluble NS1 binding to endothelial cells (250-254). Due to the unique maturation steps
of the colonial expansion of avian antibodies, we were able to generate two anti-NS1
IgY molecules that target novel epitopes on NS1. The anti-NS1 IgY preparations
demonstrated in vitro neutralization capacity similar to that of the oliogoclonal antiDENV IgY our lab has previously tested. To our knowledge this is the first anti-NS1
antibody able to inhibit infection in vitro. We went on to further characterize the binding
affinity to multiple serotypes of DENV NS1 and saw that at high concentrations anti-NS1
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IgY is able to bind multiple serotypes of DENV NS1, but at lower concentrations a
preference for DENV2 was seen in both anti-NS1-1 and NS1-8 IgY. This can be
attributed to the serotype of DENV that was originally used to make the oligoclonal antiDENV IgY, which was used to isolate the epitope specific NS1 IgY was DENV2. We
then tested the ability of anti-NS1 IgY to block soluble NS1 from binding endothelial
cells, which is the typical neutralization mechanism of anti-NS1 antibodies. We
determined that anti-NS1-1 and NS1-8 IgY were unable to block soluble NS1 from
binding to endothelial cells or inhibit vascular permeability measured by relative TEER.
This may be due to the fact that the epitopes that NS1-1 and NS1-8 target are on the
inside of the hexamer lipid complex making them inaccessible in that form. A secondary
explanation could be that the epitopes recognized by NS1-1 and NS1-8 are not required
for NS1-endothelial cell interactions. We next assessed the ability of anti-NS1-1 and
NS1-8 IgY to protect mice from lethal DENV infection. Intriguingly, NS1-8 conferred
stronger protection against DENV-induced morbidity and mortality than NS1-1.
Due to the challenges of developing immunotherapeutics for flaviviral infections
alternative therapies that do not induce ADE are critical in combating increasingly
prevalent disease burden. Avian IgY and egg powder have already been utilized to treat
veterinary and human infections and have been recognized as safe agent by the United
States Code of Federal Regulation (228). To translate anti-NS1 IgY to a human therapy
there are still challenges associated with IgY treatment that must be overcome. One
challenge that has been previously shown is that porcine and mice develop a humoral
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response to avian IgY, notably subclass IgG (230,231). Unpublished data from our lab
demonstrates that weekly immunizations with IgY in a mouse model will induce an antiIgY humoral response on the third or fourth weekly of vaccination. It is unknown if the
hosts humoral immune system recognizes IgY, which is bound to the target antigen if
the target antigen is still cleared by traditional antibody mechanisms. This would be
especially important for flaviviral treatment to ensure that the high affinity IgY remains
bound to the virus and the IgG molecule recognizing IgY would act as a trap antibody
and utilize traditional clearance mechanisms. Being that IgY is isolated directly from the
egg possible allergic reactions are a concern. It has not been demonstrated that purified
IgY can induce allergic reaction in humans. What has been demonstrated is that purified
IgY does not induce an IgE response in piglets (231). Future studies will need to be
conducted to determine any risk of harmful allergic reaction due to purified IgY.
At the moment the only licensed vaccine for Dengue infection is Dengvaxia®
Sanofi Pasteur (255). Due to apparent short comings in naïve patients which resulted in
an increased risk of developing severe symptoms the vaccine was disbanded and the
age range and serostatus criteria of patients receiving the vaccine were altered (256).
The complications associated with Dengvaxia® has lead researchers to explore other
targets for vaccine candidacy one of which is including NS1 in chimeric vaccine
strategies. This will allow for a safer vaccine profile because of the decreased risk of
ADE it will also directly target the pathogenic effects of the soluble NS1 protein that
contributes to severe pathology. Two live attenuated vaccines from NIH and Takeda
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included NS1 in their vaccine platforms (257). Human trials demonstrated that CD4+
and CD8+ T cells were induced by the vaccine NS1 protein, which solidifies the potency
and immunogenicity of including it in additional vaccines in the future (258,259).
In summary, our studies comprehensively characterized the protective capacity
of anti-DENV NS1 IgY and demonstrated that anti-DENV NS1 IgY does not induce
ADE. Our purified anti-DENV NS1 IgY preparations were able to inhibit DENV infection
in vitro and did not induce ADE at multiple concentrations. Anti-DENV NS1 IgY
antibodies were able to bind NS1 proteins from multiple serotypes, although they did not
prevent soluble NS1 from binding endothelial cells nor did they inhibit NS1-induced
hyperpermeability of endothelial cells. However, anti-DENV NS1 IgY prophylactically
administered to mice protected against lethal DENV challenge. Taken together, our data
indicate that the avian IgY platform has a promising prophylactic applications against
DENV infection, which warrants further investigation.
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Chapter VI
Discussion
The development of safe and effective anti-viral therapies is the corner stone and
highest priority to combating emerging viral pathogens around the world. Vector
competency studies should also be highly regard to know the extent in which the
pathogen could spread and what areas should be considered for the implementation of
vaccines or therapies. Our study on the vector competency of Aedes vexans was the
first demonstration of a moderate climate mosquito able to be infected with and have
the ability to transmit ZIKV. The relevance of this study impacted not only the addition of
the mosquito species to the list of possible vectors, but it greatly expanded the
geographical area in which this virus may potentially spread. Up until that study the
known vectors were the traditional tropical mosquito vectors Aedes aegypti and
albopictus both are traditional vectors of DENV as well. These two species of mosquito
are confined to tropical regions and are slowly spreading to moderate climates because
of changes in regional temperatures. The addition of Aedes vexans however to the
competent vector list instantly makes the entire moderate climate a possible location for
the spread of ZIKV. Aedes vexans is a flood water mosquito, and also one of the most
common pest mosquitoes across most of the central United States and much of Europe.
This is an excellent example of how complete vector competency profiles are necessary
to determine the extent in which a pathogen can spread. The safety and efficacy of
antibody therapy for flaviviral infections is of paramount concern. This can be extended
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to not only the development of therapeutic monoclonal antibody therapies, but also the
antibody responses elicited by a vaccine candidate. A recent cohort study in Nicaragua
determined that after primary exposure to a flavivirus there is a specific antibody titer
range in which the patient is more susceptible to ADE. This was demonstrated with not
only different serotypes of DENV but also with ZIKV. A secondary example of this is in
the recently recalled DENV vaccine Dengivax. This vaccine was developed by the
Institute of Pasteur and showed strong efficacy against DENV serotypes 1, 3, and 4 and
moderate protection against serotype 2. This was a high achievement due to traditional
antigenic bias of previous vaccines that protected strongly against one serotype and
moderate to weakly against the others. Once implemented into a high risk population
however a critical characteristic had been over looked. In patients that were
serologically naïve for DENV infection the vaccine actually increased their chance of
developing sever dengue fever on secondary naturally acquired infection. It is
hypothesized that the vaccine acted as the primary infection for these patients and
because the circulating viruses were not genomically identical to the vaccine strain the
primary antibody response held high titers of low affinity antibodies (256). Our lab’s
reports on the safety profile and advantages of anti-flavivirus IgY demonstrates that
alternative immunotherapeutics are not only effective, but preferable to the traditional
human or mouse derived antibodies because they eliminate problems such as ADE. To
expand upon the studies detailed herein our lab plans to explore the cross neutralization
capabilities of different IgY preparations between flaviviruses. Preliminary studies
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demonstrating that there is little in vitro efficacy of the oligoclonal anti-ZIKV or antiDENV2 IgY to cross reactive with the opposite virus (Fig. 14). This suggests a closer
look at the epitope mapping is needed to determine optimal cross neutralizing
antibodies to enrich future IgY preparations to enable the production of a “anti-flavivirus”
IgY stock.
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Fig. 14: Cytotoxicity of Vero cells treated with anti-DENV2 IgY infected with
ZIKV. A.) Cytotoxicity five days’ post infection of cells infected with ZIKV and ZIKV
pretreated with anti-DENV2 IgY. B.) Cytotoxicity seven days’ post infection of cells
infected with ZIKV and ZIKV pretreated with anti-DENV2 IgY.
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Another future direction of our lab is to isolate epitope specific IgY preparations from the
polyclonal anti-ZIKV IgY stock to determine novel neutralization epitopes. Due to our
prior success with anti-NS1 IgY with DENV, four stocks of anti-NS1 Zika IgY and a
highly conserved NS5 epitope were isolated and PRNT was done to determine the
extent of in vitro efficacy (Fig 15). Unlike the anti-NS1 for DENV the epitopes chosen did
not exhibit any in vitro neutralization capabilities. What is yet to be determined is if there
is efficacy of these epitopes in vivo, which is traditionally where you would see efficacy
of an anti-NS1 antibody. To further expand upon the anti-ZIKV IgY project it is yet to be
determined if IgY can cross the placental barrier to a developing fetus. This as well as
functionality of the transferred IgY would need to be determined. Once that is done the
protective efficacy of anti-ZIKV IgY to protect against trans-placental infection could be
conducted.
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vitro at 100 µg/ml.
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To continue our collaboration with the Biology department our lab plans to assist in
studies determining if microfilariae infection of the midgut of mosquitoes can increase
the dissemination rate of flaviviral infections. Previous work by Dr. Vaughan
demonstrated that alphaviruses were able to attach to the microfilariae while they exit
the midgut essentially utilizing them as a conductor to evade the midgut barrier. It was
previously thought that the virus escaped as a result of the hole in the lining of the
midgut tissue caused by the microfilariae exiting. After multiple years of working on
avian antibodies there are areas of research in which I think the lab should pursue. The
first is the production of dual specific antibodies. This has already been demonstrated
and discussed previously with rotavirus and norovirus (50). This technique could easily
be expanded to the two flaviviruses currently being studied in our lab. It would be my
recommendation to target known highly neutralizing epitopes on the envelope of the
viruses and construct a fusion protein for immunizations. It is known that the three
dimensional orientation of this epitopes can greatly impact the potency of the antibodies
being produced. As a result, extensive protein analysis would have to been done in
order to determine the conformation of the two epitopes once fused together. Not only
could this greatly expand the industrial potential of flaviviral IgY, but it could also
increase the potency of it’s immunotherapeutic value. Upon the same lines IgY
hybridoma production is necessary for IgY to take the next step into acceptance in
modern medicine. The continual production of a specific antigen immunoglobulin would
greatly cut down on quality control and quality assurance costs and variability. This is
not to say that the polyclonal IgY stocks do not have their place as therapeutics, but in
an age that is moving closer to personalized medicine specificity and targeting of
therapies is becoming increasingly valued. A final thought for the future direction of the
lab is to continue the virology aspect, but to start the process of manipulating viral
vectors for the production of antigen specific immunization. This will allow for the
production of site specific interactions while still allowing for the avian system to
recognize novel epitopes within the target protein being expressed. This could decrease
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the screening time necessary to the discovery of novel epitopes as well as increasing
the antigenicity within the avian host itself resulting in the increased production of
antigen specific IgY titers. Recently a paper described utilizing a viral vector for not only
antigenic epitope display it also encoded the genomic sequence to express a highly
potent monoclonal antibody (260). A technique similar to this could be employed to
immunize subjects against DENV NS1 which has been shown to be protective in mice
(250-254), but also to produce anti-DENV2 IgY specific for the envelope protein. This
would allow for the targeting of the traditional structural epitopes that have been shown
to have high potency, but can induce ADE and natural host immunity to a viral antigen
with protective properties devoid of ADE thus targeting the invading virus structurally
and the secondary proteins used to induce pathology.
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